Patient no.	Underlying disease	CSF WBC (cells/mm3)	Imaging pattern (MRI)	CSF HSV viral load (copies/ml)	Outcome

1	Normal	230	Fronto-temporal lesions	16,975	Complete recovery

2	Normal	350	Fronto-temporal lesions	2214	Complete recovery

3	Normal	70	Fronto-temporal lesions	Qualitative PCR	Complete recovery

4	Normal	730	Temporal lobe lesions	11,755,813	Partial recovery

5	Normal	22	Fronto-temporal and thalamic lesions	500,000	Partial recovery

6	Normal	90	Temporal lobe lesions	71,875	Complete recovery

7	Hematologic malignancy	147	Temporal lobe lesions	30,750	Complete recovery

8	Normal	75	Fronto-temporal and thalamic lesions	12,200	Partial recovery

9	DM	510	Other cortical and subcortical lesions	3325	Dead

10	Normal	40	Normal CT	1491	Partial recovery

11	Hematologic Malignancy	40	Other cortical and subcortical lesions	740	Dead

12	Normal	60	Fronto-temporal and thalamic lesions	39	Partial recovery

13	DM	15	N/A	Qualitative PCR	Partial recovery

14	Normal	600	Temporal lobe lesions	Qualitative PCR	Partial recovery

15	Old ischemic stroke	22	Fronto-temporal lesions	Qualitative PCR	Partial recovery

16	Normal	30	Temporal lobe lesions	Qualitative PCR	Partial recovery

17	Normal	20	Other cortical and subcortical lesions	Qualitative PCR	Partial recovery


Variable	Non-smoker (n = 22)	Smoker (n = 22)	t-test

 	Mean	SD	Mean	SD	t-value	P-value

Age (years)	41.5	15.8	46.0	11.4	1.1	.290

Duration of smoking (years)	NA	NA	24.3	9.7	NA	NA

Number of cigarettes smoked daily	NA	NA	17.4	7.0	NA	NA

Brinkman index	NA	NA	430	246.7	NA	NA


Pathogenic step	Candidate biomarkers	Potential approaches and targets of disease-specific therapy

Elevated production of Gd-IgA1	Serum level of Gd-IgA1 (lectin or antibody ELISA)IgA1 hinge-region O-glycopeptide profiles (mass spectrometric analysis)	Reduce production of Gd-IgA1Manipulate enzyme expression in IgA1-producing cellsReduce number of cells secreting Gd-IgA1

Production of autoantibodies specific for Gd-IgA1	Serum levels of autoantibodies (IgG and IgA) specific for Gd-IgA1	Reduce production of autoantibodies specific for Gd-IgA1Deplete cells producing the autoantibodyManipulate affinity maturation of autoantibodies to reduce affinity for the autoantigenRemove the autoantibodies from circulation

Formation of pathogenic IgA1-containing immune complexes	Circulating IgA-containing immune complexesSpecific components of circulating immune complexes	Block immune complex formation and enhance their removal from circulation and catabolismBlock epitopes of autoantigen (Gd-IgA1) by non-crosslinking antibodiesBlock autoantibodies by an epitope-containing glycopeptide or glycomimeticBlock activation of complement

Glomerular deposition and injury	Complement components and their degradation productsNovel markers of glomerular injuryUrinary immune complexesUrinary peptidomic profiles	Block activation of mesangial cellsReduce complement activation in situBlock binding of IgA1-containing immune complexes to mesangial cellsBlock mesangial-cell signaling induced by IgA1-containing immune complexes


Brain region intensity	MNI peak coordinates (X, Y, Z)	Volume	Peak activity

Precuneus	3	−69	57	120	9.2972

Posterior cingulate gyrus	0	−66	12	63	6.3883

Right medial superior frontal gyrus	3	63	9	67	6.6306

Left middle frontal gyrus	−12	33	51	30	6.0696

Left medial superior frontal gyrus	−3	30	57	74	6.6797

Left supplementary motor area	−3	15	69	52	5.598


Demographic data	Households

Number of household members	N	%

1–4 members	29	26.9%

5–8 members	32	29.6%

9–12 members	34	31.5%

>13 members	13	12.0%

Total	108	100.0%

Mean household size (members)	8.6

Median household size (members)	8

Number of children <5 in households	N	%

0 children	9	8.3%

1 children	16	14.8%

2 children	34	31.5%

3 children	29	26.9%

4 children	10	9.3%

5 children	3	2.8%

6 children	5	4.6%

≥10 children	2	1.8

Total	97	100.0

Mean number of children <5 per household	2.6

Median number of children <5 per household	2

Profession of head of household	N	%

Subsistence farmer	46	42.6%

Subsistence farmer + Daily worker	8	7.4%

Subsistence farmer + Other profession*	6	5.6%

Subsistence farmer + Farmer for trading	5	4.6%

Health worker	5	4.6%

No work	5	4.6%

Workman	4	3.7%

Subsistence farmer + Hunter	4	3.7%

Subsistence farmer + Teacher	3	2.8%

Subsistence farmers + Other professions†	14	13.0%

Other professions‡	7	6.5%

Missing	1	0.9%

Total	108	100.0%


	HIV-infected	Healthy controls

LTNP	Normal progressors

Number	5	13	7

Median age, years	49	39	41

Median CD4 cells, cells/μl	1240	565	n.a.

Median Log (viral load)	1.7	4.3	n.a.


Model	Covariates included	OR (95% CI)*	Pvalue

1	Long PPI exposure (2 or more days)	2.19 (1.27 – 3.78)	.005

H2RA use	1.12 (0.70 – 1.79)	.628

Antibiotic use	2.53 (1.23 – 5.23)	.012

Immunosuppression	0.79 (0.51 – 1.23)	.297

2	Long PPI exposure (2 or more days)	2.08 (1.26 – 3.43)	.004

Antibiotic use	2.53 (1.25 – 5.29)	.010

Immunosuppression	0.79 (0.51 – 1.22)	.282

3	Long PPI exposure (2 or more days)	2.03 (1.23 – 3.36)	.006

Antibiotic use	2.52 (1.23 – 5.18)	.012


	MBA failures	MBA controls	p-Value

Transportal ACLR (n = 26)	25.0	20.7	<0.001

Transtibial ACLR (n = 28)	24.0	20.3	0.003


Factor	Respondents(n = 56)

Comorbidities of parturient	31 (55)

BMI	39 (70)

Quality of SAD seal	42 (75)

Fasting status 	24 (43)

Other

 Team skill	2 (4)

 Clinical situation	2 (4)

 Speed of surgeon	2 (4)


Genes	Forward primer(5′‐ 3′)	Reverse primer(5′‐ 3′)

GAPDH	CGCTAACATCAAATGGGGTG	TTGCTGACAATCTTGAGGGAG

HIF‐1α	AAGCCCAGAGTCACTGGGACT	GTACTCACTGGGACTGTTAGGCTC

BMP‐2	GAAGCCATCGAGGAACTTTCAG	GGAAATTTTGAGCTGGCTGTG

Runx2	ACTCTGCCGAGCTACGAAATG	GGGACCGTCCACTGTCACT

COL‐I	CCGTGACCTCAAGATGTGCC	GAACCTTCGCTTCCATACTCG

OST	GATGCGGTCCCTAGTTCTACC	CCTCCAGTGAGTGGGATGTTT

OPN	AGCACACAAGCAGACGTTTTG	GCAACTGGGATGACCTTGATAG

ERK1	CTGGCTTTCTGACCGAGTATGT	AATTTAGGTCCTCTTGGGATGG

ERK2	GCACCAACCATTGAGCAGAT	TCACGGTGCAGAACATTAGCT

p38	AGATGCCGAAGATGAACTTCG	GGTCAGGCTCTTCCATTCGT

JNK	TCCAGCACCCGTACATCAAC	TCTTAGTTCGCTCCTCCAAATC


Participant (diagnosis)	Trauma type	Psychotic symptoms	Target hotspot and associated memory	Key tf-CBTp; phase 4 intervention

P1Primary: unspecified non-organic psychosisSecondary: PTSD	Childhood; multipleSought asylum in the UK	Auditory command hallucinationsVisual hallucinationsParanoia	Witnessing murder of childhood friend; childhood physical abuse; held captive and tortured	Cognitive restructuringReliving with CRImagery rescripting (for nightmares and visions)

P2Primary: schizophreniaSecondary: severe depressive episode with psychotic symptoms	Adult; single event	Auditory command hallucinationsPersecutory beliefs	Living in conflict zone and held at gunpoint by terrorists	Cognitive restructuringReliving with CR

P3Primary: other non-organic psychotic disorderSecondary: PTSD	Childhood; multipleSought asylum in the UK	Auditory hallucinationsVisual, tactile, and olfactory hallucinationsPersecutory beliefs	Living in conflict zone (civil war/genocide); parents killed. Held captive and gang raped; witnessed murder of grandfather	Cognitive restructuringImagery rescripting

P4Primary: unspecified non-organic psychosisSecondary: none	Childhood; single event	Auditory command hallucinationsVisual and tactile hallucinationsPersecutory beliefs	Rape in childhood	Cognitive restructuringImagery rescripting for trauma event and visual hallucinationsSchema work

P5Primary: PTSDSecondary: emotionally unstable personality disorder	Adult; multiple	Auditory command hallucinationsVisual, olfactory, and tactile hallucinationsPersecutory beliefs	Several rapes and extreme physical assaults (long-term domestic violence); stillbirth of child	Cognitive restructuringReliving with CR for trauma eventsImagery rescripting for visual, olfactory tactile, and hallucinations

P6Primary: severe depressive episode with psychotic symptomsSecondary: none	Childhood; single event	Auditory hallucinationsPersecutory beliefs	Physical and emotional abuse	Imagery rescriptingSchema work

P7Primary: schizophreniaSecondary: severe depressive episode with psychotic symptoms	Adult; single event	Auditory hallucinationsVisual, tactile, and olfactory hallucinationsPersecutory beliefs	Being threatened with a knife	Cognitive restructuring reliving with CR

P8Primary:PTSDSecondary: severe depressive episode with psychotic symptoms	Adult; multipleSought asylum in the UK	Commanding voicesVisual and tactile hallucinationsPersecutory beliefs	Long-term imprisonment with physical and sexual torture. Witnessing murder in prison	Cognitive restructuring reliving with CRImagery rescripting

P9Primary: severe depressive episode with psychotic symptomsSecondary: none	Childhood; multiple	Auditory command hallucinationsVisual and tactile hallucinationsPersecutory beliefs	Repeated childhood physical abuse	Cognitive restructuringImagery rescripting for trauma events, visual and tactile hallucinations, and nightmares


Complain	n of cases	n of positive cases

Discharge	750	20 (2.7%)

Discharge and itching	120	10 (8.3%)

Discharge, itching and burning sensation	130	20 (15.4%)

Total	1000	50

P value	0.129


Pancreatitis	Neoplastic conditions	Other

Acute	34.4 %	pancreatic ACC	19.8 %	fistula	2.3 %

Chronic	15.3 %	n. r.	9.9 %	transplant rejection	1.5 %

		NEC	4.6 %

		adeno-carcinoma	3.8 %	anastomotic leakage	0.8 %

		IPMN	3.1 %

		other	4.6 %

Total	49.6 %	total	45.8 %	total	4.6 %


Test variable	Schizophrenia patients (24)	Healthy adults (24)

	M	SD	M	SD

Age	42.43	6.85	40.63	6.66

Education (in years)	10.5	3.41	11.08	2.78

Digit span forward	4.58	1.31	5.00	1.59

Digit span backward	4.08	1.38	4.88	1.73

PANAS pos	29.05	4.90	31.25	3.23

PANAS neg	18.95	4.25	22.29	6.67

BPRS

Total	22.56	3.14

Positive symptoms	7.31	1.67

Negative symptoms	3.56	1.80


Gene	Forward	Reverse

18s rRNA	CCCAGTGAGAATGCCCTCTA	TGGCTGAGCAAGGTGTTATG

Scleraxis	CCCAAACAGATCTGCACCTT	ATCCGCCTCTAACTCCGAAT

Tenascin-C	AACCCGTCCAAAGAGACCTT	GCGTGGGATGGAAGTATCAT

Tenomodulin	GTCCCTCAAGTGAAGGTGGA	CCTCGACGGCAGTAAATACAA

Collagen type-1 alpha 1	TGCGAAGACACCAAGAACTG	GACTCCTGTGGTTTGGTCGT

Cartilage oligomeric matrix protein	AGAACATCATCTGGGCCAAC	CGCTGGATCTCGTAGTCCTC

Thrombos pondin-4	GGGAAATGGGGTTACCTGTT	CGGGTAGCAGGGATGATATT


	Level of guidance	Nature of guidance	Health Technology

Meta regression findings	Number of sessions not related to outcome	Better outcomes where guidance provided, and where based on CBT	No differences between technologies (email, telephone, face to face)

Meta synthesis findings	No relevant findings	No relevant findings	No relevant findings

Consensus exercise	Agreement on timing, duration, and number of sessions	Agreement that patient preference should determine the nature of guidance	Agreement that health technology should be accessible, and help with literacy problems.

Incorporated into the intervention	3–10 sessions, 15–30 minutes duration over 5–12 weeks	CBT based. Patient preference delivery of guidance	Devised a self-help manual and also a CD

	Who should deliver guided self-help	Personal experience of depression	Ambivalent help seeking and covert presentation of problems

Meta regression findings	No differences in outcome between professional and paraprofessionals	No relevant findings	No relevant findings

Meta synthesis findings	No relevant findings	Personal experience characterised by feeling of inability to cope, and disturbances to functioning. Use of lay language/metaphors important	Point in illness trajectory where people make service contact, and their prior contact with other help may determine acceptability

Consensus exercise	Most frequent were nurses and primary care graduate workers. Specific training needed	Mixed response to inclusion of lay language and metaphors. Agreement on importance of social functioning, and relapse prevention	None relevant

Incorporated into the intervention	Primary care graduate workers or other mental health professionals	Emphasised return of social functioning. Lay language, metaphors and causal explanations included. Relapse prevention incorporated	Expectations and prior contact emphasised and included in the intervention. Choices and patient preference for interventions included

	Control and helplessness in engaging with treatment	Stigma associated with treatment	Patients' understanding of self-help

Meta regression findings	No relevant findings	No relevant findings	No relevant findings

Meta synthesis findings	Patients reported coping strategies such as distraction, or the use of locations associated with feelings of safety and control	Extent to which guided self-help acknowledges issues of stigma likely to determine acceptability	Seeing the self as the agent of change may be very important

Consensus exercise	Mixed response but emphasis on collaborative working, patient centred goals, and roles i.e. patient as change agent	None relevant	Agreement of collaborative working, explicitly detail roles of both patient and MHW i.e. patient as change agent, coach as facilitator

Incorporated into the intervention	Highlighting intervention as a method of regaining control and incorporating use of coping strategies termed 'respite' in the intervention	Discussed guided self-help as requiring a sense of acting on the world and enhancing self-worth	Explicit team rationale, with the patient as 'team captain', facilitator renamed as 'self-help coach'


Variable		Range

Sex, M/F	33/41

Age, years	63.5 ± 1.1	38–78

BMI, kg/m2	23.0 ± 4.0	13.7–35.3

Smoking status, ever/never	31/43

CTD

RA/SSc/PMDM/SjS/MCTD/	24/14/14/11/5

SLE/overlap syndrome	1/5

Surgical lung biopsy, yes/no	33/41

Corticosteroids/immunosuppressant	23/10

FVC, % predicted	81.0 ± 19.1	38.3–127.0

DLco, % predicted	57.1 ± 19.2	22.6–113.6

RV, % predicted	81.2 ± 31.5	17.9–181.9

TLC, % predicted	80.3 ± 18.3	47.9–138.6

PaO2, mmHg	80.8 ± 9.9	60.2–103.2

A-a gradient, mmHg	20.2 ± 11.5	−3.8–38.1

MPAP, mmHg	17.2 ± 5.5	8–36

CI, l/min/m2	3.59 ± 0.77	1.89–5.18

PVR, Wood units	127.3 ± 59.9	34.0–406.0

PVRI, Wood units/m2	223.5 ± 102.1	52.0–606.0


Locus	Alleles	Parasitaemia	χ2 significance

Low (< 1,000/μl)	Moderate to high (≥1,000/μl)

Pfcrt 76	Mutant	8	31	<0.001

Wild	23	13

Pfcrt 271	Mutant	0	4	0.138*

Wild	31	40

Pfcrt 326	Mutant	0	9	0.009*

Wild	31	35

Pfcrt 356	Mutant	1	17	<0.001*

Wild	30	27

Pfcrt 371	Mutant	22	36	0.409

Wild	9	8

Pfmdr1 -86	Mutant	0	4	0.138*

Wild	31	40

Pfmdr1 -1246	Mutant	0	3	0.263*

 	Wild	31	41


Data subset	Accuracy	Accuracy (%)	False positives	False negatives	MCC score

All samples	2290 of 2315	98.92	2 of 2159	23 of 156	0.91

EC origin cells	558 of 564	98.94	0 of 535	6 of 29	0.89

EN origin cells	849 of 857	99.07	1 of 790	7 of 67	0.93

M origin cells	1015 of 1030	98.54	3 of 944	12 of 86	0.9

Random non-channel subset	2221 of 2315	95.94	13 of 2006	81 of 309	0.81


Primary antibody	Host	Manufacturer; catalog no.; dilution	Secondary antibody

Enhanced chemiluminescent (ECL) detection

 Anti-phospho-S6 (P-S6) Ser235/236	Rabbit	Cell Signaling Technology, Beverly, MA; #4858; 1:500 in 5 % BSA in TBS-Ta	Anti-rabbit IgG, HRP-conjugated; Cell Signaling Technology, Beverly, MA; #7074; 1:10000 in 5 % nonfat milk in TBS-T

 Anti-S6 (S6)	Rabbit	Cell Signaling Technology, Beverly, MA; #2217; 1:1000 in 5 % BSA in TBS-T

 Anti-mTOR	Rabbit	Cell Signaling Technology, Beverly, MA; #2983; 1:1000 in 5 % BSA in TBS-T

 Anti-caspase-3	Rabbit	Cell Signaling Technology, Beverly, MA; #9662; 1:1000 in 5 % BSA in TBS-T

 Anti-GFP	Rabbit	MBL International Corporation, Geel, Belgium; #598; 1:2000 in 5 % nonfat dry milk in TBS-T

 Anti-Elmo1	Rabbit	Eurogentec, Liege, Belgium; custom orderb; 1:500 in 5 % nonfat dry milk in TBS-T

 Anti-α-tubulin	Mouse	Sigma-Aldrich, St. Louis, MO; #T5168; 1:20,000 in 5 % nonfat dry milk in TBS-T	Anti-mouse IgG, HRP-conjugated; Cell Signaling Technology, Beverly, MA; #7076; 1:10000 in 5 % nonfat milk in TBS-T

 Anti-β-actin-HRP	Mouse	Sigma-Aldrich, St. Louis, MO; A3854; 1:15,000 in 5 % nonfat dry milk in TBS-T	N/A

Immunofluorescence

 Anti-phospho-S6 (P-S6) Ser235/236	Rabbit	Cell Signaling Technology, Beverly, MA; #4858; 1:200 in 1 % donkey serum in PBS-Tc	Anti-rabbit IgG Alexa Fluor 488; Life Technologies, Carlsbad, CA; A-21206; 1:500 in 1 % donkey serum in PBS-T

 Anti-c-Fos	Rabbit	Santa Cruz Biotechnology, Santa Cruz, CA; #7202; 1:200 in 1 % donkey serum in PBS-T

 Anti-GFAP	Mouse	Millipore, Darmstadt, Germany; #04-1031; 1:500 in 1 % donkey serum in PBS-T

 Anti-GFP	Mouse	MBL International Corporation, Geel, Belgium; #598; 1:1000 in GDB bufferd


Type of study	Complete articles	Abstracts	Total	No. of Patients

All studies	8	2	10	249

Prospective	5	1	6	106

Retrospective	3	1	4	143

De novo use of RTX	6	1	7	179

RTX used for refractory AMR	2	1	3	70

Pediatric	1	0	1	20

Adult	7	2	9	229


Strain	Maximum specific growth rate (h-1)

HZ848	0.15 ± 0.01

HZ848-siz1Δ	0.19 ± 0.00

W303a	0.19 ± 0.01

W303a-siz1Δ	0.30 ± 0.01


	Initial polysomnography	Titration studya	At therapeutic pressureb

Time in Bed (min)	355	360	84.5

Total Sleep Time (min)	277.5	253	83

Stage N1 (%/min)	3.6/10	4/10	35/29

Stage N2 (%/minutes)	29.2/81	25.1/64	15/12

Stage N3 (%/minutes)	49.5/137	43.3/110	~1/<1

REM (%/minutes)	17.7/49	27.7/70	50/42

Obstructive Apneas	23	1	0

Hypopneas	96	30	4

Central apneas	39	14	1c

REM central apneas	39	14	1c

Mixed apneas	7	0	0

Time below 90% O2 saturation (%)	22.9	4.7	0


	Function	cis element	Sequence	Position	TF family

1	Defense against insect herbivory	AtMYC2 BS in RD22	CACATG	(1578-1583)	BHLH

2	Development	Bellringer/Replumless /Pennywise	AAATTAAA	(2593-2600)	Homeobox

3	Development	Bellringer/Replumless /Pennywise	AAATTAGT	(1368-1375)	Homeobox

4	Development	Bellringer/Replumless /Pennywise	ACTAATTT	(293-300)	Homeobox

5	Response to hiperosmolarity	ATB2/AtbZIP53/AtbZlP44/GBF5 BS in ProDH	ACTCAT	(2537-2542)	bZIP

6	Auxins response	ARFI binding site motif	TGTCTC	(177-182) (1820-1825)	ARF

7	ABA response	DPBF1&2 binding site motif	ACACTAG	(897-904)	bZIP

8		MYB binding site promoter	AACCAAAC	(2359–2366)	MYB

9	Defense and stress	MYB4 binding site motif	AACAAAC	(825-831) (775-781) (2446-2452)	MYB4

10	Leaf maturation and senescence	RAVI-A binding site motif	CAACA	(1-5) (2138-2142) (1508-1512) (583-587) (360-367)	ABI3VPl

11	Development	LFY consensus binding site motif	CCAATG	(1413-1418)	LFY

12		Boxll promoter motif	GGTTAA	(2810-2815)

13	Drought response	DRE-like promoter motif	TACCGACCA	(533-541)

14	Light response	GATA promoter motif [LRE]	TGATAG	(2957-2962)

15	Light response	GATA promoter motif [LRE]	AGATAA	(287-292) (96-101)

16	Light response	GATA promoter motif [LRE]	TGATAA	(2308-2313)

17		Hexamer promoter motif	CCGTCG	(649-654)

18		T-box promoter motif	ACTTIG	(1529-1534)


Region	States in region	Selected states, medical colleges, and cities

North	Delhi, Rajasthan, Jammu and Kashmir, Himachal Pradesh, Punjab, Haryana, Uttarakhand and Chandigarh	NCT of Delhi (Lady Harding Medical College, Delhi), Rajasthan (NIMS Medical College and Hospital, Jaipur)

South	Tamil Nadu, Karnataka, Kerala, Andhra Pradesh, Puducherry, Lakshadweep, Andaman and Nicobar	Karnataka (Kasturba Medical College, Manipal), Tamil Nadu (Madras Medical College, Chennai)

East	Sikkim, Assam, Tripura, Manipur, Nagaland, Arunachal Pradesh, Mizoram, Meghalaya, Bihar, Jharkhand, West-Bengal and Orissa	Manipur (Regional Institute Medical Sciences, Imphal), Orissa (Kalinga Institute of Medical Sciences, Odisha)

West	Dadar and Nagar Haveli, Daman and Diu, Goa, Maharashtra and Gujarat	Gujarat (M.P. Shah Medical College, Jamnagar), Maharashtra (L.T.M. Medical College and General Hospital, Mumbai)

Central	Uttar Pradesh, Chhattisgarh, and Madhya Pradesh	Uttar Pradesh (Integral Institute of Medical Sciences and Research, Lucknow), Madhya Pradesh (G.R. Medical College, Gwalior)


Risk Factor Goals

Blood Pressure	BP 130/80 mmHg

Diabetes Mellitus	Fasting or pre-prandial glucose of 4-6, or a HbA1C < 6.5%

Lipids	Total cholesterol less than 4 mmol/l or an LDL < 2.0 mmol/l

Smoking	Smoking cessation

Weight	BMI < 25


Compositional Category	Features in Chloroplast

CP genome length (nt)	155,989

LSC length (nt)	85,912

SSC length (nt)	17,517

IR length (Ira/b) (nt)	52,560

AT/GC contents (%)	62.34/37.66

No. of total/unique genes	129/111

Genic occupancy (nt)	88,065

Intergenic occupancy (nt)	67,924

Protein-coding genes	78

Transfer RNAs (tRNAs)	29

Ribosomal RNAs (rRNAs)	4

No. of genes duplicated in IR regions	16

Total number of genes with intron(s)	17

Gene(s) with single intron	14

Gene(s) with multiple introns	3

tRNAs with intron(s)	5


Data Set	Score Used	Positive	Negative	Close to Zero	Total Tested

Ma–Mu	Sum of signs of translation shift scores	597	569	58	16,942

Fa–Fu	Sum of signs of translation shift scores	48	60	5	15,045

Fa–Fu	Count of CpG	84	85	15	12,491


Participant	Outcome measure	Instrument	baseline	3 months	6 months

Patient	Self-perceived performance in daily activitiesa	Canadian Occupational Performance Measure (COPM; performance rating) [25]	√	√	√

 	Self-perceived satisfaction with performance in daily activities	Canadian Occupational Performance Measure (COPM; satisfaction rating) [25]	√	√	√

 	Objective performance in daily activities	Perceive Recall Plan Perform system (PRPP) [26]	√	√	-

 	Participation	Activity Card Sort (ACS) [27,28]	√	√	-

 	 	Utrecht Scale for Evaluation of Rehabilitation Participation (USER-P; satisfaction part) [29,30]	√	√	√

 	Health-related quality of life	Parkinson’s Disease Questionnaire (PDQ-39) [31-33]	√	√	√

 	Impact of fatigue	Fatigue Severity Scale (FSS) [34,35]	√	√	√

 	Mood	Becks Depression Inventory (BDI) [36]	√	√	√

Caregiver	Perceived caregiver burden	Zarit Burden Interview (ZBI) [37]	√	√	√

 	Objective caregiver burden	Objective care burden questionnaire; hours of care	√	√	√

 	Mood	Hospital Anxiety and Depression Scale (HADS) [38]	√	√	√

Both	Quality of life	Euroqol EQ-5 D [39]	√	-	√

 	Quality of life overall	Visual Analogue Scale for Quality of life; VAS QoL	√	√	√

 	Proactive coping	Utrecht Proactive Coping Competence scale (UPCC) [40]	√	√	√

 	Resource utilization	Resource utilization questionnaire: patient and caregiver version	√	√	√


Birth defects	Number of cases	Birth prevalence/10,000 and 95%CI

Anencephaly	0	0 (0–6.3)

Spin bifida	1	1.7 (0–9.5)

Encephalocele	0	0 (0–6.3)

Microcephaly	1	1.7 (0–9.5)

Arhinencephaly/holoprosencephaly	4	6.8 (1.9–17.4)

Hydrocephaly	4	6.8 (1.9–17.4)

Buphtalmos	1	1.7 (0–9.5)

Congenital cataract	2	3.4 (0.4–12.3)

Anotia/microtia	1	1.7 (0–9.5)

Transposition of great vessels	4	6.8 (1.9–17.4)

Tetralogy of Fallot	2	3.4 (0.4–12.3)

Ventricular septal defect	42	71.3 (51.4–96.4)

Atrial septal defect	4	6.8 (1.9–17.4)

Endocardial cushion defects	3	5.1 (1.1–14.9)

Ebstein's anomaly	1	1.7 (0–9.5)

Hypoplastic left heart syndrome	0	0 (0–6.3)

Coarctation of aorta	3	5.1 (1.1–14.9)

Choanal atresia, bilateral	0	0 (0–6.3)

Cleft palate without cleft lip	1	1.7 (0–9.5)

Cleft lip with or without cleft palate	2	3.4 (0.4–12.3)

Oesophageal atresia/stenosis	4	6.8 (1.9–17.4)

Congenital hypertrophic pyloric stenosis	1	1.7 (0–9.5)

Small intestine atresia/stenosis	0	0 (0–6.3)

Anorectal atresia/stenosis	1	1.7 (0–9.5)

Hirschsprung's disease	1	1.7 (0–9.5)

Anomalies of intestinal fixation	0	0 (0–6.3)

Hypospadias

Indeterminate sex	0	0 (0–6.3)

Renal agenesis	1	1.7 (0–9.5)

Cystic kidney	3	5.1 (1.1–14.9)

Bladder exstrophy	0	0 (0–6.3)

Polydactyly and syndactyly	4	6.8 (1.9–17.4)

Total limb reduction defects	Not analysed	Not analysed

Diaphragmatic hernia	1	1.7 (0–9.5)

Omphalocele	0	0 (0–6.3)

Gastroschisis	0	0 (0–6.3)

Trisomy 13	0	0 (0–6.3)

Trisomy 18	0	0 (0–6.3)

Down syndrome	6	10.2 (3.7–22.2)

Prader Willi syndrome	0	0 (0–6.3)

Total	98	166.4


Service area	Number of MNH providers observed	Number of provider-client interactions observed	Intraclass Correlation Coefficient (ICC)

Total	Inter-vention group	Com-parison group	Total	Inter-vention group	Com-parison group	Cluster level	Inter-vention group	Com-parison group

ANC	63	29	34	232	118	114	Facility	0.551	0.458

							Provider	0.763	0.667

Labor & delivery	117	57	60	226	123	123	Facility	0.632	0.474

							Provider	0.775	0.454

PNC	109	57	52	229	119	110	Facility	0.530	0.573

							Provider	0.658	0.574


Anti-VLY scFv	Expression level, % of total cell protein	Oligomeric state	Activity (%) after 12 months storage at 4°C

scFv 9B4 (VL-VH)	20-30	monomeric	100

scFv 9B4 (VH-VL)	20-30	monomeric	100

scFv 23A2 (VL-VH)	20-30	monomeric	75

scFv 23A2 (VH-VL)	20-30	monomeric	75


Characteristics	% (SE)

Age, yb	45.2 ± 0.2

 < 65	86.2 (0.6)

 ≥ 65	13.8 (0.6)

Sex

 Male	49.5 (0.5)

 Female	50.5 (0.5)

BMI, kg/m2

 < 25	68.9 (0.9)

 ≥ 25	31.1 (0.9)

Smoking exposure

 Never	74.3 (0.7)

 Former or current	25.7 (0.7)

Alcohol drinking, g/day

 < 30	90.1 (0.6)

 ≥ 30	9.9 (0.6)

Residence area

 Rural	20.2 (1.8)

 Urban	79.8 (1.8)

Education

 ≤ High school	70.4 (1.0)

 ≥ College	29.6 (1.0)

Occupation

 Agriculture & fishery	5.6 (0.6)

 Industry	9.2 (0.5)

 Services	85.3 (0.8)

GFR, ml/min/1.73 m2b	95.1 ± 0.5

Blood pressureb

 SBP, mmHg	116.9 ± 0.4

 DBP, mmHg	76.7 ± 0.3

 MAP, mmHg	88.7 ± 0.2


Comparison	Keyword	Gene Set	Gene Set Description	Size	p-valueExp. 2	Significant Genes	p-valueExp. 1

Control vs ALC-NTO/ALC-NTC (see legends)	Growth,Growth Regulation*	GO:0016049GO:0040007	^Cell growth^Growth	4775	0.0020.005	(Ctgf, Igfbp2, Emp1, Osm, Cyr61, Gap43, Crim1, Tgfb3, Igfbp7, Nov, Emp3), Gpc3, Csf1, Socs2, Bmp6, Bmp4, Inhbb, Lepre1, Wrn, Wig1, Cish	0.0100.010

		GO:0001558GO:0040008	Regulation of cell growthRegulation of growth	3956	0.0020.016	(Ctgf, Igfbp2, Osm, Cyr61, Gap43, Crim1, Igfbp7, Nov), Gpc3, Csf1, Socs2,	0.0060.017

		GO:0005520	Insulin-like growth factor binding	14	0.000	Ctgf, Igfbp2, Cyr61, Crim1, Igfbp7, Nov	0.012

	Heart*	GO:0001525	Angiogenesis	53	0.022	Ctgf, Anxa2, Cyr61, Thbs1, Vegfa, Tie1, Elk3, Flt1, Crhr2, Vegfc, Kdr, Bmp4, Adra2b, Tnfrsf12a	0.022

	Eye#	GO:0001654	Eye Development	26	0.040	Mab21l1, Neurod1, Neurod4, Ntrk2, Fkbp8, Bmpr1b, Crb1, Stat3, Tspan5, Pax6, Bmp4, Map3k1	0.004

	Epigenetic factor~,^	GO:0006334	Nucleosome modeling	30	0.021	Hist3h2b, a; Hist1h3f; Hist1h1c; Hist1h2b, c; Hist1h3a; H1f0; Smarca2; Nap1l3	0.033

ALC-NTO vs ALC-NTC	Growth, Growth retardation	GO:0007173	Epidermal growth factor receptor (EGFR) signaling pathway	5	0.019	Pde6g, Egfr, Hbegf(Enriched in ALC-NTC)	0.023


Criterion	Response	No.	Mean ± SD	p-Value

Occupational exposure (mean ± SD)

 Yes	Bone Pb	108	14.4 ± 0.50a	< 0.001

 No		99	3.22 ± 0.50a

 Yes	Blood Pb	107	2.73 ± 2.39	< 0.001

 No		98	1.25 ± 2.10

Smoked ever/never

 Yes	Bone Pb: exposed	65	18.1 ± 0.61a	0.002

 No		43	6.87 ± 0.86a

 Yes	Blood Pb: exposed	64	3.67 ± 12.0	< 0.001

 No		43	1.76 ± 2.49

Ever used estrogen

 Yes	Bone Pb: referent	29	7.73 ± 0.94a	0.003

 No		70	1.41 ± 0.60a

 Yes	Blood Pb: referent	28	1.56 ± 2.21	0.038

 No		70	1.15 ± 2.03

Still have menstrual periods

 Yes	Blood Pb: referent	59	1.04 ± 1.97	0.002

 No		39	1.65 ± 2.14

 Yes	Blood Pb: exposed	46	2.09 ± 2.49	0.012

 No		61	3.33 ± 2.19

Surgical menopause

 Yes	Blood Pb: exposed	47	2.87 ± 2.12	0.008

 No		14	5.46 ± 2.02

Postmenopausal women who have used estrogen

 Yes	Bone Pb: referent	24	9.18 ± 1.08a	0.007

 No		16	1.83 ± 1.32a

Ever used oral contraceptives

 Yes	Bone Pb: referent	73	1.39 ± 0.61a	0.036

 No		26	7.22 ± 0.90a

 Yes	Blood Pb: referent	72	1.13 ± 2.00	0.006

 No		26	1.66 ± 2.66


Parameter	(n = 504)

Age (Years)

 <50 Years	422 (84)

 >50 Years	82(16)

Sex

 Male	423(84)

 Female	82(16)

Pre existing comorbid conditions

 Respiratory disease	51 (10)

 Renal Disease	27 (50)

 Malignancy	25 (5)

 Hypertension	11 92)

 Diabetes mellitus	5 (1)

Signs and symptoms

 Pain	495 (98)

 Vomiting	296 (59)

 Abdominal distention	221 (44)

 Constipation	193 (38)

 Fever	124 (25)

 Diarrhoea	35 (7)

 Tachycardia (pulse >/110/minute)	115 (23)

 Hypotention (Systolic blood pressure <100 mm Hg)	44 (9)

 Urine output (<30 ml/hr)	80 (16)

 Tacchypnea (respiratory rate >20/minute)	334 (66)

Investigations

 Pneumoperitoneum on Chest X-Ray	340(67)

 Air fluid levels on abdominal X-Ray	108(21)

 Hyponatraemia(Na<130 mEq/L)	148(29)

 Hypokalemia(K<2.7 mEq/L)	44(09)

 Blood Urea Nitrogen(>167 mg/dl)	76(15)

 Serum Creatinine(<1.7 mg/dl)	65(13)


Group	n	Before therapy	After therapy

Met + Acu Group	49	5.57 ± 0.257	3.23 ± 0.170***△△

Control Group	49	5.50 ± 0.244	4.25 ± 0.197***


Practice related variables	Percentage (%)

Monitor blood glucose

 Daily	10 (8)

 Weekly	18 (15)

 Monthly	45 (37)

 Never	49 (40)

Blood pressure monitor

 Daily	12 (10)

 Weekly	4 (3)

 Monthly	49 (40)

 Never	57 (47)

Adherence to medication

 Regular	53 (43)

 Irregular	69 (57)

Visiting an eye specialist

 Every 6–12 months	13 (11)

 Every year	45 (37)

 Felt problem with vision	64 (52)


Species	Population	Hostplant	Coordinates

T. bartmani	JL	Abies concolor	34.170000	-117.002017

T. bartmani	RS	Abies concolor	34.210000	-117.098333

T. boharti	ML	Adenostoma	32.881200	-116.445917

T. californicum	Fremont	Adenostoma	36.763517	-121.502533

T. californicum	HW1	Quercus	36.286933	-121.841883

T. chumash	HW2	Adenostoma	34.269700	-118.168483

T. chumash	ED	Ceanothus	33.885183	-116.859783

T. cristinae	WTA	Adenostoma	34.515833	-120.073150

T. cristinae	OJ	Ceanothus	34.485300	-119.298117

T. knulli	Trail	Sequoia	35.836200	-121.391483

T. knulli	BC	Ceanothus	36.071017	-121.595567

T. petita	Ma	Ceanothus	36.358900	-121.900350

T. petita	Mo	Ceanothus	36.476533	-121.936133

T. podura	HW243	Adenostoma	33.815117	-116.791033

T. podura	Seq	Ceanothus	35.583333	-118.533333

T. poppensis	Fish	Pseudotsuga	38.885283	-123.517150

T. poppensis	Mado	Sequoia	36.996433	-121.717783

T. cristinae	OGA	Adenostoma	33.990567	-116.061417

T. cristinae	R23A	Adenostoma	34.519067	-120.077500

T. cristinae	SC	Ceanothus	34.522300	-119.831283

T. cristinae	PEC	Ceanothus	34.491333	-119.795017


PHASE	ACTIVITY	PURPOSE	LOGISTICS	PARTICIPANTS	OUTPUTS

1.Max.5 × 8hourshifts	Initial unstructuredobservations	• Familiarisation with space and use of space• Familiarisation with rhythm of setting• Starting to build relationships and trust• Determine who is amenable to shadowing• Identify key locations for stationaryobservations• Identify key policy/guideline documents	• Background observation ofactivity (potentiallyaccompanying key initialcontact in the setting)• Introductions with staffmembers• 5 shifts on different days ofthe week (over 2 weeks)(= max 40 hours)	All staff	• Map of settings• Timetable of key regular events• List of 6-8 key informants• Collected documents for lateranalysis (e.g. policies, guidelines)• Fieldnotes

2.Max.8 × 8hourshifts	Shadowing staffmembers	• Observe mechanics of interactionalconstruction of safe practice• Observe interactions newcomers/old-timers• Observe use of tools/artefacts/environment• Identifying key practices to follow in laterstage	• Shadow each staff memberfor 1 shift/part shift• Audio recording of keymeetings attended by staffmember• Field notes of informal talk• Field interviews	2 doctors2 nurses2 allied health2 managers	• Map of practices of each keyinformant - how they construepatient safety and how they goabout trying to maintain it• Fieldnotes• Transcriptions of meetings

3.Max.2 × 8hourshifts	Stationaryobservations in keylocations	• Observe role of key artefacts in constitution ofsafety (e.g. phone in nurse's station; filingcabinet etc).• Observe patterns of movement of staff	• 2 locations, 1 shift each(max. 16 hours)	All staff	• Fieldnote account of how artefactsand space play a role in theconstitution of safety• Actor-artefact network map

4.Max.4 × 8hourshifts	Tracing keypractices	• Observe the unfolding of specific practicespreviously identified as key to preservation ofsafety• Observe differences in activity when practice isin the course of the everyday (e.g. admission/discharge) and, if appropriate, when it followsbreakdown in order (e.g. incident review)	• 1 'everyday' practice overthe course of 2 shifts• 1 practice dealing withdeviation from the normal (i.e.when safe practice hasbroken down in some way)	Staff involved inpractices chosen	• Map of 'practice nets' involved inpractices key to preservation ofsafety• How practice nets change whensafety breaks down

5.Approx.1 hr perinterview	Interviews	• Elicit narrative accounts of safety preservation• Observe how the meaning of safety isconstructed by different professionals - what'rules and resources' do they draw on?• Test emerging findings/maps of practices	• 6-8 interviews - audiorecordings	6-8 key informantsfrom phase 2	• Transcripts for analysis

6.Approx.30 minspersurvey	•Social networksurvey	• Provide triangulation of observation andinterview data• Map overall patterns of communication aboutsafety issues within and between the twosettings under study	• Administer a social networkquestionnaire to all staff in theinpatient team andcommunity team under study.	All staff	• Social network diagrams providingvisual representation of patterns ofsafety communication


	Mycotoxin Content (μg/kg) a

	% >LOD	Mean	SEM b	Median	90th Percentile	Maximum

DON	66	473	99	100	2510	9880

ZEA	22	18	7	5	47	1000

NIV	25	16	3	3	75	290


Country	Discount	Annual cash flow (profit/loss)	Present value of annual cash flow	Present value of all annual cash flows	Present value of terminal valuea	Total present valueb

Singapore	50% annually	3.13	0.41	1.51	4.13	5.64

25% annually	3.13	1.03	3.15	10.27	13.41

15% annually	3.13	1.56	4.42	15.58	20.00

Netherlands	50% annually	10.76	1.42	6.06	14.17	20.23

25% annually	10.76	3.53	12.12	35.27	47.39

15% annually	10.76	5.35	16.80	53.51	70.31

USA	50% annually	−94.76	0	0	0	0

25% annually	−94.76	0	0	0	0

15% annually	−94.76	0	0	0	0


Order	 Symbol	Name	Similarity	Parameter	Remark

1	CENP-E	kinesin	0. 8169	3

2	GCN4	 	0.7611	3	monomer yeast transcriptional activator

3	ROCK1	Serine kinase	0.7394	3	Rho-associated,coiled-coil containing protein kinase 1

6	CENP-B	 	0.7297	3

4	PAK1	 	0.6481	3	P21 activated kinase

7	GP41-HIV	 	0. 6010	3

8	ATG12	 	0.4749	3

5	ROCK2	 	0.4478	3

9	CENP-A	 	0	0


Measurementa	No. (%)

Range of motion (knee)	34 (57)

X-ray (knee)	19 (32)

Pain score (knee)	10 (17)

Subjects were asked to first stand and then walk along a 10 m walkway	5 (8)

Range of motion (shoulder)	5 (8)

Pain score (shoulder)	5 (8)

Stability of joint function (stabilometry)	4 (7)

Pain score (upper limb)	4 (7)

Hand grip strength	3 (5)

Range of motion (hip)	3 (5)

Strength of the knee extensors	3 (5)

Chair rise test	2 (3)

Muscle power (shoulder)	2 (3)

Range of motion (ankle)	2 (3)

Range of motion (finger/wrist)	2 (3)

Range of motion (lower limb, matching task)	2 (3)

X-ray (elbow)	2 (3)

X-ray (hip)	2 (3)

X-ray (shoulder)	2 (3)


Compound	Adsorption capacity, μmol g−1	Distribution coefficient (k), g L−1

1-Naphthol	62	200

2-Naphthol	60	170

Resorcinol	59	190

Phenol	0 ± 2	–


Parameters	Pre-treatment	First weekpost-treatment	Second weekpost-treatment

Volume of ejaculate (ml)	0.30 ± 0.02 *	0.23 ± 0.02	0.15 ± 0.02*

Color of ejaculate	Milky to creamy white	Milky to creamy white	Milky to creamy white

Sperm motility 	85% *	80%	70% *

Spermatozoa viability	96% *	90%	83% *

Sperm concentration (x 109/ml)	428 ± 4.26 *	341 ± 6.63 *	289 ± 4.81*


Variable	N° total dogs	N° positiveT. annaedog (%)

Age (years)	≤3	65	53 (81.54)**

>3	47	22 (46.81)

unknown	8	0

Sex	Male	58	38 (65.5)

Female	55	37 (67.2)

unknown	7	0

Size (kg)	≤22	77	59 (76.6)*

>22	35	16 (45.71)

unknown	8	0

Breed	Pure breed	86	53 (61.6)

Crossbreed	33	22 (66.6)

unknown	1	0

Lifestyle	Hunting	75	56 (74.6)*

Companion	28	13 (46.4)

Guard	12	6 (50)

unknown	5	0

Habitat	Rural	96	64 (66.6)

Urban	24	11 (45.8)

Tick infestation	Yes	50	35 (70)

No	49	27 (55.1)

unknown	21	13 (10.8)

Seasonality	spring	20	14 (70)

summer	20	10 (50)

autumn	60	38 (63.3)

winter	20	13 (65)


Parameter	Correlation coefficient (r)	p value

CD11avs.sICAM-1	0.317	>0.01

CD11avs.sVCAM-1	0.366	> 0.01

CD11bvs.sICAM-1	0.251	> 0.05

CD11bvs. sVCAM-1	0.258	> 0.05

CD49dvs.sICAM-1	0.315	>0.01

CD49dvs.sVCAM-1	0.419	> 0.01

sICAM-1vs.TNF-α	0.355	>0.01

sVCAM-1vs.TNF-α	0.419	> 0.01


Male	60 (67%)

Age

 20–40 years of age	52 (58%)

 41–50 years of age	21 (23%)

 >50 years of age	17 (19%)

Practitioner type

 Attending physician	56 (62%)

 Resident	13 (14%)

 Extender	21 (23%)

Experience

 1–5 years	38 (42%)

 >5–10 years	15 (17%)

 >10 years	37 (41%)

Practice facility

 Academic	54 (60%)

 Private or community	32 (36%)

 Urgent care	4 (4%)

Average annual census

 <30 k	5 (6%)

 30–75 k	33 (37%)

 >75 k	52 (57%)


Parameter	South Asian	Western European	p-value

WB SAS	0.7 ± 0.8	1.8 ± 2.3	0.10

Head/neck SAS	0.5 ± 1.1	1.9 ± 4.0	0.21

Aorta SAS	0.9 ± 2.6	1.3 ± 3.1	0.59

Abdomen SAS	1.8 ± 3.8	3.2 ± 4.4	0.26

Iliofemoral SAS	0.0 ± 0.0	1.9 ± 6.9	0.048

Run-off SAS	0.7 ± 2.2	0.9 ± 2.9	0.77

Normal vessels	501 (97%)	1117 (95%)	0.2

Vessels with 1–50% stenosis	14 (3%)	46 (4%)	0.1

Vessels with 51–70% stenosis	1 (0.2%)	9 (0.8%)	0.08

Vessels with 71–99% stenosis	0	3 (0.2%)	0.3

Occluded vessels	0	1 (0.01%)	0.3


Occupational exposure	Never smokers	Former smokers	Current smokers	P valueb

No.	%	No.	%	No.	%

Never exposed	52	70.3	38	48.7	32	69.6	Reference

Ever exposed (any agent)	22	29.7	40	51.3	14	30.4	0.01

 Wood dust	12	16.2	21	26.9	10	21.7	0.10

 Leather dust	10	13.5	17	21.8	2	4.3	0.01

 Nickel compounds	0	0.0	2	2.6	2	4.3	0.23

 Chromium compounds	1	1.4	3	3.8	0	0.0	0.16

 PAH	0	0.0	1	1.3	1	2.2	0.47

 Cork dust	1	1.4	0	0.0	0	0.0	0.51


RIO—Psychosocial Measure	Coefficient of Correlation

Temp. Fingers—Temp. Nose	0.450	**

—Interference General (BPI)	−0.390	*

—Interference Affective (BPI)	−0.517	*

—Interference Relationship (BPI)	−0.437	*

—Interference Sleep (BPI)	−0.600	***

—Interference Enjoy (BPI)	−0.665	***

—Pain (NAS of SF-MPQ)	−0.584	**

—Loneliness (L-UCLA)	−0.487	**

Temp. Chin—Temp. Maxillofacial	0.483	**

—Temp. Nose	0.459	**

—Internal Control of Anger (STAXI-2)	0.383	*

—Alexithymia (TAS)	−0.446	*

—Supression (EQR)	−0.481	*

Temp. Maxillary—Temp. Nose 	0.821	***

—Interference Sleep (BPI)	−0.520	**

—Interference Enjoy (BPI)	−0.461	**

—Pain (NAS of SF-MPQ)	−0.504	**

Temp. Nose—Interference Sleep (BPI)	−0.443	*

—Pain (NAS of SF-MPQ)	−0.413	*

Temp. Periorbital—Temp. Forehead	0.469	**

—Reappraisal (EQR)	−0.485	*


Experiment	Total reads	Aligned reads	Mean PCR duplicates (%)	Aligned reads on target	On-target rate (%)	Uniquely aligned readsa	Uniquely aligned reads on targeta	On-target rate (%)a	Mean coverage on target

dCATCH-SeqCATCH-Seq	853,358841,154	414,965802,931	47.42.8	382,625291,808	92.2136.34	406,331762,445	379,084289,558	93.2937.98	145.98110.18


Regression indices and explanatory variable	Dependent variable‡

Eggs	Excreta

Intercept	-1.33** (0.45)	2.97** (0.23)

Regression coefficients

Area (Reference: Faridpur)

Madaripur	0.46** (0.15)	0.09 (0.08)

Chandpur	-0.29* (0.15)	0.01 (0.08)

Satkhira	-0.28 (0.15)	0.02 (0.08)

Jessore	-0.22 (0.15)	0.03 (0.08)

Age (weeks)	0.01** (0.00)	-0.00 (0.00)

Feed type (Reference: Commercial feed)	0.00 (0.13)	0.06 (0.07)

Arsenic in drinking-water (ppb)	0.41** (0.03)	0.44** (0.02)

Arsenic in feed (ppb)	0.40** (0.09)	0.52** (0.04)

R2	0.55	0.82

F value	36.83**	133.42**


Secure environment (SE) employment type	Less than 10 years	11 – 20 years	21 – 30 years	Over 30 years	TOTAL

GPs predominantly employed in SE	3	8	8	4	23

GP principals	1	2	4	2	9

TOTAL	4	10	12	6	32


	National sponsors	International sponsors

When to report adverse events	Frequency	Frequency

Serious adverse events

 No later than 1 hour	0	0

 No later than 24 hours	0	31

 No later than 7 days	1	2

 No later than 15 days	0	1

 Others	0	5

 Did not specify	30	32

 Total	31	71

Unexpected adverse events

 No later than 1 hour	0	1

 No later than 24 hours	0	12

 No later than 7 days	1	1

 No later than 15 days	0	3

 Others	0	6

 Did not specify	30	48

 Total	31	71


	Mean (SD) or %

Age, mean (SD)	63.5 (13.8)

 18–45, %	11.5%

 46–70, %	51.5%

≥ 71, %	37.0%

Male, %	35.3%

Marital status, %

 Married	70.7%

 Single	3.7%

 Widowed/Separated/divorced	25.6%

Living alone, %	15.2%

Level of education, %

≤ Elementary	47.9%

 Middle School	16.7%

 High School	23.8%

≥ University	11.7%

Employment status, %

 Regular/long-term	25.0%

 Non-regular/temporary	23.5%

 Unemployed	2.5%

 Economically inactive/students	50.0%

Medical aid, %	8.3%

Perceived social status	3.6 (1.5)


Clinical features	Pathoanatomy	Treatment based approach	Screening/Prediction tool	Pain mechanisms

Barker 1990 [79]	2	Bernard and Kirkaldy Willis 1987 [41]	2	Albert et al. 2012 [61]	4	Fritz et al. 2007 [64]	3	Schafer et al. 2009 [65]	5

Ben Debba et al. 2000 [36]	3.5	Cassisi et al. 1993 [38]	3	Hall et al. 1994 [49]	5	Roach et al. 1997 [63]	3	Smart et al. 2011 [66]	5

Glassman et al. 2011 [37]	2.5	Hahne et al. 2011 [38]	3	Mckenzie 1981 [49]	5.5	Scholz et al. 2009 [62]	4	Nijs et al. 2015 [75]	2.5

Nachemson and Andersson 1982 [80]	3.5	Paatelma et al. 2009 [44]	3.5	Delitto et al. 2012 [48]	3.5

Spitzer et al. 1987 [25]	4	Petersen et al. 2003 [39]	4

Sweetman et al. 1992 [26]	2.5	Vining et al. 2013 [46]	3.5


Gene	Primer	Sequence	Amplicon	Tm (°C)

GK	Forward	5′-CATATGTGCTCCGCAGGACTA-3′	105 bp	61.7

	Reverse	5′-CTTGTACACGGAGCCATCCA-3′

HK	Forward	5′-ACCCACGAAACAACACCATCA-3′	69 bp	79

	Reverse	5′-GACGTACAACAATGGCTCACTAAAG-3′

PFK-1 (L)	Forward	5′-TTACCGATCACCCTCGTTCCT-3′	80 bp	84

	Reverse	5′-TTCCCCTTAGTGCTGGGATCT-3′

PFK-1 (M)	Forward	5′-GTGGACACTGATATGACCATTGG-3′	67 bp	82

	Reverse	5′-ATGGCGTCCACGATCTCTACA-3′

G6Pase	Forward	5′-GGATCTACCTTGCGGCTCACT-3′	132 bp	62.7

	Reverse	5′-TGTAGATGCCCCGGATGTG-3′

F16BP	Forward	5′-CGTCCTATGCTACCTGTGTCCTT-3′	73 bp	81

	Reverse	5′-CCCCTCTTCTCGGGCTCTATTAT-3′

PEPCK	Forward	5′-GCAACTTCTCTCGGCTCGTT-3′	99 bp	62.7

	Reverse	5′-TGGCAGTTCTACTGGGCTACAC-3′

G6PDH	Forward	5′-GATGGCCTTCTACCCGAAGAC-3′	72 bp	82

	Reverse	5′-GCGGATGTCATCCACTGTGA-3′

P13K	Forward	5′-CCTGAAAGAGCTGGTGCTACATT-3′	71 bp	81

	Reverse	5′-GTGTGACATTGAGGGAGTCATTG-3′


Sampling time (expression change)	Ischemia-related	PACAP-related	PACAP in ischemia-related	Common: ischemia-related and PACAP in ischemia-related	Common: PACAP-related and PACAP in ischemia-related

6 h (upregulated)	1,237	435	839	171	43

6 h (downregulated)	622	743	498	31	24

24 h (upregulated)	2,759	263	831	49	30

24 h (downregulated)	2,104	271	1468	28	75


	JIA-associated NIU (n = 14)	Pure NIU (n = 11)	Total

Bilateral (pts)	12/14	11/11	23/25

Total eyes with NIU	24	22	46

Location:

Anterior/Posterior/Panuveitis	12/6/2	2/4/2	16/7/2


	Current	Projected

		Only MVA3	MVA/Misoprostol4

Procedure type distribution for first trimester, legal, induced abortion

MVA ($17)		100 %	70 %

Misoprostol-alone ($10)		-	30 %

Total annual cost	$314,008[$287,406 - $502,522]	$250,332	$219,408

Percent decrease from current costs	-	20 %	30 %


Compound	Inhibitor concentration (mg/L)

Furfural	19.65 ± 0.81

Hydroxymethylfurfural (HMF)	3.89 ± 0.25

Glucuronic acid	ND

p-coumaric acid	ND

Syringic acid	ND

Ferulic acid	ND


Targeted neurotransmitter	Agents under investigation	Status	Ref.

Acetylcholine	LatrepirdineHuperzine A	(III)	76

GABA	SGS742	(II)*

ADS‐8704 (NMDA antagonist)	(III)

Serotonin	5HT1A	Lecozotan	(II)

5‐HT4	PRX‐03140TD‐8954	–

5‐HT6	SB‐742457	(II)

Histamine	PF03654746AB288	(I)(II)

Adenosine	SCH58261	–


Factors	Outcome (n = 10)

Boiling/treatment of drinking water:	Yes	0

No	10 (100%)

Regular hand washing after toilet use:	Yes	3 (30%)

No	7 (70%)

Regular hand washing after handling pork with:	Soap	9 (90%)

Sanitizer	0

Water only	1 (10%)

Wearing of hand gloves and aprons at work:	Yes	0

No	10 (100%)

Consumption of pork:	Yes	10 (100%)

No	0

Roasting and eating pork while handling raw pork:	Yes	4 (40%)

No	6 (60%)

Method of pork processing for consumption:	Cooked	4 (40%)

Cooked and fried	2 (20%)

Roasted	4 (40%)

Knowledge on public health significance of Taenia solium:	Yes	0

No	10 (100%)


	N	(%)

Uterine atony	179	(55)

Placenta abnormalities;	173	(53)

 Retained	54	(17)

 Previa	37	(11)

 Abnormally invasive placenta	32	(10)

 Remnant	30	(9)

 Abruption	20	(6)

Laceration;	40	(12)

 Vagina	23	(7)

 Cervix	17	(5)

Uterine rupture	20	(6)

Iatrogenic during/after cesarean	11	(3)

Other	22	(7)

Unknown	9	(3)


	Apical segment	Middle segment	Basal segment

Wild-type	207 ± 50	253 ± 23	247 ± 27

ugt78d2	194 ± 17	118 ± 14*	142 ± 18*


Outcome: any type ofTP53-mutationsin a tumor	HR	95% CI	p-value

Having both disruptiveTP53-mutationsandUGT2B17-deletions	2.22	1.30 to 3.80	0.004

p16-positive tumor	0.53	0.29 to 0.99	0.047

Stage IV	2.32	1.44 to 3.74	0.001

Poorly differentiated tumor grade	1.66	1.01 to 2.74	0.047


	Accuracy	Mean Absolute Error	Area under the ROC Curve

Logistic Regression	80.0%	0.201	0.854

Bayesian Network	96.4%	0.129	0.931

Artificial Neural Network	96.4%	0.045	0.941


	Silica Gels	Zeolites	ALPOS/SAPOS	Composites	MOFs	Activated Carbons

Adsorption heat (kJ/kg)	160 ÷ 180 *	50 ÷ 300*	250 ÷ 300 *	50 ÷ 250*	20 ÷ 200 **	45 ÷ 900 ***

Typical desorption temperatures [°C]	50 ÷ 80	70 ÷ 350	60 ÷ 90	60 ÷ 90	60 ÷ 150	80 ÷ 200

Density (kg/m3)	650 ÷ 700	650 ÷ 900	800 ÷ 900	300 ÷ 600	1000 ÷ 2000	700 ÷ 750

Specific heat (kJ/kgK)	0.8 ÷ 0.9	0.85 ÷ 0.95	0.85 ÷ 0.95	0.95 ÷ 1.05	0.8 ÷ 1.2	0.8 ÷ 1.5

Thermal conductivity (W/mK)	0.15 ÷ 0.20	0.15 ÷ 0.25	0.15 ÷ 0.25	0.15 ÷ 0.30	0.10 ÷ 015	0.15 ÷ 0.75

Possible refrigerants	water	water	water	water, methanol, ethanol	water, methanol, ethanol	methanol, ethanol, ammonia

Amount of uptake exchanged in a typical cyle [g/g]	0.03 ÷ 0.10	up to 0.2	up to 0.25	up to 0.8	0.16 ÷ 0.40	015 ÷ 0.60


	Study 1	Study 2

Location	Newcastle, Australia	Bad Nauheim, Germany

Aim	Develop model, Determine spontaneous recanalization rate	Determine recanalization rates with microbubble + sonothrombolysis enhancement of tPA

Primary Outcome [method]	Recanalization [Laser Doppler]	Recanalization [Laser Doppler]

Secondary Outcome(s) [method]	Infarct Volumes [TTC], Mortality, Neurological Deficit scores	Clot lysis [Inspection of the major branches of the cerebral arterial circulation]

Survival post-embolism	24 h	2 h

Treatment groups (n)	No treatment (n = 7)	Saline (n = 10), tPA (n = 10), tPA + Ultrasound + BR38 microbubbles (n = 10)

Laser Doppler Monitoring	Continuous	Discontinuous

To 4 h post-embolism	Pre-embolism, Post-embolism, Pre-treatment, Post-treatment


RASgrf1	primers	Length (bp)

Segment 1	Forward TTTGTGAGGAAAGATGGTGTTGReverse AAACCATAAAAACCTTCACATAACTAC	349

Segment 2	Forward GTAGAGAAGAGGAAAATAAGGAGGReverse CGAAAACCCCTAAAAATATTACAC	347


#	Code	Site Name	Country	N	Latitude	Longitude

1	GRO	Grosbeak Lake	Canada	11	59.792	-111.996

2	FOR	Forgotten Pass Lake	Canada	2	59.58	-111.451

3	HAY	Hay Camp Lake	Canada	3	59.541	-111.465

4	TUR	Estany d'en Turies	Spain	7	42.243	3.103

5	CHI	Salada de Chiprana	Spain	8	41.239	-0.182

6	ERA	Laguna de las Eras	Spain	10	41.202	-4.582

7	SA2	Balsa de Santed II	Spain	10	41.016	-1.542

8	GAL	Laguna de Gallocanta	Spain	5	40.974	-1.508

9	TON	Torreblanca Marsh, Poza Norte	Spain	4	40.148	0.17

10	TOS	Torreblanca Marsh, Poza Sur	Spain	12	40.146	0.168

11	MAN	Laguna de Manjavacas	Spain	9	39.416	-2.866

12	TIA	Tianjin	China	3	39.158	117.176

13	SAL	Laguna del Salobrejo	Spain	5	38.914	-1.469

14	PET	Laguna de Pétrola	Spain	9	38.84	-1.566

15	MOJ	Laguna de Mojón Blanco	Spain	2	38.798	-1.432

16	SLD	Laguna del Saladar	Spain	4	38.789	-1.419

17	HOY	Laguna de Hoya Rasa	Spain	2	38.785	-1.428

18	CAS	Laguna de Casa Nueva	Spain	2	38.776	-1.433

19	ATA	Laguna de Atalaya de los Ojicos	Spain	3	38.773	-1.43

20	CLO	Clot de Galvany	Spain	2	38.246	-0.546

21	FUE	Laguna de Fuente de Piedra	Spain	2	37.109	-4.767

22	CAP	Laguna de Capacete	Spain	5	37.016	-4.842

23	EEL†	Eel Pond	Japan	4	34.717	136.533

24	ATL	Atlit coast	Israel	1	32.703	34.94

25	SAP	Sapelo	USA	1	31.5	-81.219

26	EIL	Eilat	Israel	1	29.56	34.967

27	MEA	Meagher Pond	USA (Caribbean)	1	19.295	-81.232

28	WAN	Lake Wannamal	Australia	2	-31.109	116.049

29	PEA	Pearse's Lake	Australia	3	-31.629	116.914

30	YEN	Yenyenning Lakes	Australia	1	-32.235	117.233

31	HOT	Hotham River	Australia	1	-32.64	116.977

32	BUS	Bushy Swamp	Australia	2	-33.541	117.27

33	DUN	Dunn's Swamp	Australia	1	-33.924	120.155

34	BUL	Lake Bulla	Australia	1	-34.755	142.361

35	COL	Lake Colongulac	Australia	2	-38.173	143.163

36	TOH	Tower Hill Lake	Australia	5	-38.325	142.368


	Number of	BMI	Time of smoking	Average number of smoked cigarettes	Passive smoking at work	Passive smoking at home

Subjects	Women	Men	Women	Men

Urine

 Smokers	26	16	10	22.2	24.9	In the evening	6–10	Yes	Yes

 Passive smokers	25	13	12	23.01	22.32	n/a	n/a	Yes	Yes

 Control group	16	10	6	20.7	22.2	n/a	n/a	No	No

Saliva

 Smokers	11	8	3	22.7	24.2	In the evening	1–5	No	Yes

 Passive smokers	16	11	5	22.4	23.1	n/a	n/a	No	Yes

 Control group	10	7	3	21.8	23.4	n/a	n/a	No	No


Sr. No. 	Formulation 	Droplet size (nm)	Zeta potential (mv)

1 	AILP – A 	246	-0.232

2 	AILP – B 	213	-0.114

3 	AILP – C 	200	-0.535

4 	AILP – D 	144	-0.596

5 	AILP – E 	136	-0.185


Combination Label	Transfer Function (Hidden Neuron)	Transfer Function (Output Neuron)	No. of Output Neurons

CA	logsig	logsig	4

CB	tansig	logsig	4

CC	logsig	logsig	2

CD	tansig	logsig	2

CE	logsig	purelin	1

CF	tansig	purelin	1


Tracking method – mechanism	Disadvantages	Advantages

GFP, luciferase – DNA transfer can be mediated virally (transduction), via liposomes (lipofection), or by electrical parameters (electroporation/transfection)	- Genetic manipulation of cells may alter their function	- Human ASCs with GFP or luciferase resume proliferation normally

- Since they are cytosolic in location; the vector (mRNA/DNA) and/or the protein (GFP) could be transmitted to host cells via fusion elements and/or microvesicle secretion, resulting in contamination. Hence, there is concern for false positivity and their detection may not equate to viability of donor cells	- Detection is sensitive to in vivo non-invasive bioluminescence imaging

- Technique requires serial passages, not suitable for use with fresh uncultured cells

- Many mammalian tissues have endogenous fluorescence

BrdU – this nuclear marker is a thymidine analog that replaces (3H) thymidine and can penetrate cell membranes to incorporate into newly synthesized DNA strands of actively proliferating cells	- Optimal labeling requires longer incubation time	- BrdU labeling has no effects on the ASC differentiation/proliferation and is not cytotoxic

- Not suitable for non-invasive methods of detection

- Does not indicate viability

- Cells lose BrdU rapidly with serial passages

Lipophilic dyes (DiI, DiR) –long-chain carbocyanine dyes with long aliphatic tails that incorporate into the lipid regions of the cell membranes	- Rapidly contaminates neighboring cells by macrophage-mediated phagocytosis, exchange of membrane microdomains, microvesicle and/or exosome transfer	- Easy technique for labeling and identification of cells

- May be cytotoxic to cells

- The dye fades with serial passages

Amine reactive probes (CFSE) – these diffuse into cells and react with cytosolic amine-containing residues to form dye–protein adducts that are retained	- The dye is toxic to ASCs	- Good staining efficiency

- Not suitable for in vivo non-invasive imaging

- Does not correlate with viability

- Contamination of neighboring cells can occur via macrophage-mediated phagocytosis, microvesicle and/or exosome transfer

Nanoparticles – small crystals made up of inorganic molecules; for example, iron oxide, cadmium	- Can be toxic to cells in high concentration and detection is difficult with low concentrations	- Photostable, remain resistant for long periods of time

- Contamination of neighboring cells can occur via phagocytosis, microvesicles and/or exosome transfer	- Can be used for in vivo non-invasive imaging

- Does not correlate with viability

Real-time PCR for endogenous retroviral sequence (ERV-3) – the gene is present as a single copy in the human genome and so can be used to detect the presence of transplanted human cells in animal models	- Not suitable for non-invasive methods of detection	- Gives a quantitative estimate of number of cells

- False positives can occur by macrophage-mediated phagocytosis but this is very low	- Very sensitive and specific

	- The gene is already present in the human cells, so there is no need to stain the cells

FISH detection of human-specific cell surface markers or Alu sequences	- Alu sequences occur in large numbers in the primate genome, which makes higher likelihood of a false positive detection by transmission to host cells/macrophages via microvesicles/exosomes	- The gene is already present in the human cells, so there is no need to stain the cells

- Not suitable for non-invasive methods of detection

- Does not correlate with viability


Features	Bt X022	Bt 4.0718

Chromosome size	5,460,989 bp	5,641,982 bp

Number of plasmids	7	6

Predicted CDSs	5888	6797

Hypothetical genes	1592	1826

ncRNAs	148	94

Predicted insecticidal genes	4	6


Signal + harmonic	Frequency estimation (Hz)	Error (Hz)

Mean (μ)	Standard deviation (σ)	Mean (μ)	Standard deviation (σ)

2nd	60.0000	0.0000	0.0000	0.0000

3rd	60.0000	0.0000	0.0000	0.0000

3rd + 5th	60.0000	0.0000	0.0000	0.0000


Clinical observations and epidemiological arguments

(I)	The prevalence rates of OCS in schizophrenia increased after market approval of SGAs such as clozapine.

(II)	The comorbidity rates in later stages of schizophrenia are higher than during the ARMS or at first manifestation of psychosis.

(III)	In parallel to antipsychotic treatment OCS manifest de novo or show a marked aggravation.

(IV)	High prevalence rates of OCS are observed during CLZ treatment.

(V)	Schizophrenia patients with SGA-induced OCS markedly contribute to the entire sample of comorbid patients.

Evidence derived from pharmacological considerations

(I)	Pharmacodynamic properties modulate the risk for OCS: marked difference between samples treated with first generation antipsychotics or mainly dopaminergic SGAs (such as aripiprazole or amisulpride) compared to CLZ.

(II)	OCS manifest as an unfavourable drug effect de novo during treatment with potent antiserotonergic SGAs such as CLZ.

(III)	Indicators of a dose-effect relation: the severity of OCS is positively correlated with duration, dosage, and serum levels of CLZ treatment.

(IV)	OCS severity persists over time in patients under stable CLZ treatment.

(V)	The severity of OCS improves after reduction of CLZ dosage to minimally sufficient levels (due to augmentation or combination).


Classification of Theileria gene pairsa	Theileria consecutive gene pairs with orthologs in P. falciparumc	Pairs in Theileria with conserved synteny in Plasmodiumb	Percent conserved pairsd

Opposite strand	940	64	22.66

Opposite strand Overlap	182	64	35.16

Same-strand	805	125	15.53


Focus groups	Age category	Gender	Relationship

More homogeneous groups

	< 50 yrs	50 + yrs	Female	Male	Spouse	Other

Group A	2	5	5	2	6	1

Asian Indian = 5

Asian Pakistani = 2

Group B	1	6	4	3	2	5

Asian Indian = 7

Group C	0	5	2	3	4	1

White British = 5

Group D	0	3	3	0	3	0

White British = 3

Group E	3	4	5	2	2	5

Black Caribbean = 3

Black African = 4

More heterogeneous groups

Group F	0	5	3	2	4	1

Asian Indian = 1

Asian Pakistani = 2

Black Caribbean = 1

White British = 1

Group G	2	5	7	0	7	0

Asian Indian = 4

Black African = 1

White British = 1

Black Caribbean = 1

Total = 41	8	33	29	12	28	13


Factor	Numerator df	Denominator df	F	P

Support level	4	528	5.36	0.0003

Stimulus intensity	9	528	211.62	<0.0001

Background EMG	1	528	0.88	0.3497

Support × Stimulus	36	528	0.83	0.7505

Support × Background	4	528	2.34	0.0542

Stimulus × Background	9	528	1.41	0.1805

Support × Stimulus × Background	36	528	1.10	0.3248


Rank	Name and cell line	Mean 	N	Enrichment	P	Specificity

12	Estradiol-ssMCF7	0.700	2	0.989	0.00016	0.0000

31	Estradiol-HL60	0.303	8	0.590	0.00335	0.1585

3091	Estradiol-MCF7	0.222	19	0.485	Null	Null

3580	Estradiol-PC3	-0.040	8	0.223	Null	Null


CBT	MRT

Treatment focus on perpetuating factors	Treatment focus depending on the relation between the(precipitating, predisposing and perpetuating) factorsand the presented complaints.

Afterwards feedback at next therapy session	Immediately feedback during therapy

Pays no attention to physical sensations	Stimulating awareness of healthy bodily symptoms

CBT	CBT incorporated with principles of mindfulness


Type of nerves	Outcome variables

Peripheral nerve function (N = 50)	 Number of nerves involved (N = 50)

Normal, n (%)	Abnormal, n (%)	<2, n (%)	≥2, n (%)

Motor nerve	23 (46)	27 (54)	36 (72)	14 (28)

Sensory nerve	14 (28)	36 (72)	23 (46)	27 (54)

Mixed nerve	10 (20)	40 (80)	15 (30)	35 (70)


Standard	Mean ± SD of Score	Standard Achieved*(% of notes)

Contents	14.4 ± 2.1	16 (6.8)

Legibility	3.9 ± 0.2	232 (99.1)

ANKLe	18.4 ± 2.1	61 (26.1)


Criteria	Exclusion	Method

Significant co-morbid disease that would threaten safety or impair ability to participate in interventions or testing, previous acute knee injury, bilateral severe tibiofemoral OA, severe patellofemoral OA (JSN = 3 using OARSI atlas), no definite medial tibiofemoral OA, severe obesity, low weight.	Symptomatic or severe coronary artery disease; severe HTN; active cancer other than skin cancer; anemia; dementia; liver disease; COPD; peripheral vascular disease; inability to walk without an assistive device; blindness; type 1 diabetes; type 2 diabetes on thiazolidinedione agents; bilateral severe medial tibiofemoral OA (KL = 4), no definite medial tibiofemoral OA (KL = 0, 1), BMI < 20 or > 45 kg.m-2	Medical history; physical exam; PA and skyline knee x-ray; height and weight.

OA disease location and alignment restrictions: predominant knee OA other than medial tibiofemoral OA; valgus, or extreme varus alignment.	Lateral tibiofemoral OA > medial tibiofemoral OA, severe patellofemoral OA; valgus knee alignment > 2°, or varus alignment > 10°	Knee PA and skyline view x-rays, lower extremity long x-ray.

Excess alcohol use	≥ 21 drinks per week	Questionnaire

Inability to finish 18-month study or unlikely to be compliant	Lives > 50 miles from site or planning to leave area ≥ 3 months during the next 18 months	Questionnaire, interview

Conditions that prohibit CT	BMI > 45 kg.m-2	height and weight

Significant cognitive impairment	diagnosis of dementia or a MoCA score <20	Medical history, MoCA

Low Pain	Pain ≤ 3 on a scale from 0-20	WOMAC


Cancer	Mean age ± SD at diagnosis of CD

Non Hodgkin's lymphoma	46.1 ± 13.8

Small bowel	59 ± 10

Colon	51.3 ± 9.4

Stomach	53.5 ± 15.4

Hodgkin's lymphoma	54.3 ± 6

Breast	41.2 ± 12.8

All neoplasms	47.6 ± 10.2


Compound Described	Mechanism of Action	Targeting	References

PRIMA-1Met (APR-246)	Converted to MQ; MQ binds to thiol groups in the core domain of mutp53 to restore wtp53 function	Restoration	Bykov 2002 [66], 2005 [67]Lambert 2009 [68], 2010 [69]

PhiKan083 or PhiKan7088	Binding to p53-Y220C specific core cavity and restore wtp53-like folding	Restoration of p53 Y220C	Boeckler 2008 [70]Liu 2013 [71]

PEITC	Unknown; p53-R172H specific; restores wtp53-like function 	Restoration of p53 R172H	Aggarwal 2016 [72]

ReACp53	Small peptide; blocks amyloid-like aggregation of mutp53 to shift to wtp53-like folding state	Deaggregation, Restoration	Soragni 2016 [73]

pCAP	Small peptide; binds preferentially to mutp53 when it transiently exhibits wtp53-like conformation to shift the equilibrium towards the wtp53	Stabilize wtp53 structure	Tal 2016 [74]

ZMC-1	Metallochaperone; increases intracellular zinc level to restore zinc-deficient p53 mutants such as p53-R175H which allows proper wtp53-like folding	Restoration and activation	Yu 2012 [75]Blanden 2015 [76]

RETRA	Not well known; disrupts mutp53/p73 complexes 	Activation of p73	Kravchenko 2008 [77]

Prodigiosin	Not well known; induces TAp73 expression and disrupts its interaction with mutp53	Activation of p73	Hong 2014 [78]

Chetomin (CTM)	Binds to Hsp40 and increases the binding of Hsp40 to p53 R175H which leads to restoration of wtp53 conformation	Restoration of p53 R175H	Hiraki 2015 [79]

Hsp90 inhibitors	e.g., 17AAG and Ganetespib; disrupt chaperone complexes to release and activate MDM2 and/or CHIP which degrade mutp53	Mutp53 degradation	Esser 2005 [35]Li 2011 [37]Alexandrova 2015 [15]

Statin	e.g., Lovastatin inhibits Hsp40 (by decreasing mevalonate-5-phosphate) or Cerivastatin (more potent) inhibits Hsp90 (by inhibiting HDAC6) to release and reactivate CHIP and MDM2 leading to mutp53 degradation	Mutp53 degradation	Parrales 2016 [60]Ingallina 2018 [59]


Attribute and level	Available coloura

Treated (T) or untreated (U)	Shape	Size (feet)	Price (000 TSH)

T (Olyset brand)	Rectangular	4 × 6	2, 4, 6, 8	Aqua blue

T (Olyset brand)	Rectangular	6 × 6	2, 4, 6, 8	Navy blue and whiteb

U (Safinet brand)	Rectangular	4 × 6; 6 × 6	2, 4, 6, 8	White

U (Safinet brand)	Conical	3.5 × 6c; 6 × 6	2, 4, 6, 8	White


Source of variation	df	SS	MS	Est. variance	Variation (%)	P

Among individuals	83	2276.02	27.42	8.36	70.7	< 0.001

Within individuals	157	543.45	3.46	3.46	29.3

Total	240	2819.47		11.83	100


Cancer. related Function	PLS predicted Target genes in the respective functions	The nos. of cancer related miRNAs associated with the mRNA targets

Cancer	ANXA2, BHLHE40, CANX, CAPG, COTL1, CYBA, DDIT4, FTL, GPX1, GSTP1, IFITM1, MIF, MMP11, OAZ1, ODC1, S100A11, SLC12A8, SLC7A11, SOX4 and UBE2I (20)	15

Tumorigenesis	ANXA2, BHLHE40, CANX, CAPG, COTL1, CYBA, DDIT4, FTL, GPX1, GSTP1, IFITM1, MIF, MMP11, NUDT1, OAZ1, ODC1, PRDX2, S100A11, SLC12A8, SLC7A11, SOX4 and UBE2I (22)	15

Carcinoma	ANXA2, BHLHE40, CANX, COTL1, CYBA, FTL, GSTP1, IFITM1, MMP11, OAZ1, ODC1, S100A11 and SLC7A11 (13)	12

Malignant tumor	ANXA2, BHLHE40, CANX, COTL1, CYBA, FTL, GPX1, GSTP1, IFITM1, MIF, MMP11, OAZ1, ODC1, S100A11, SLC7A11 and SOX4 (16)	12

Primary tumor	ANXA2, BHLHE40, CANX, COTL1, CYBA, FTL, GPX1, GSTP1, IFITM1, MIF, MMP11, OAZ1, ODC1, PRDX2, S100A11, SLC7A11 and SOX4 (17)	12

Angiogenesis	ANXA2, CANX and GPX1 (3)	8


Severity of inflammatory cell infiltration	Score 1 (n=7)	Score 2 (n=10)	Score 3 (n=17)	Score 4 (n=12)

Patients without TBM-IgG3	4	3	2	6

Patients with mild deposited TBM-IgG3	3	7	9	4

Patients with strong deposited TBM-IgG3	0	0	6	2


Target	Primer	Sequence (5′ → 3′)	Ta (°C)	Reference

Total bacteria	UniF	GTGSTGCAYGGYYGTCGTCA	60	[23]

UniR	ACGTCRTCCMCNCCTTCCTC

Bifidobacterium	BIF-F	TCG CGTC(C/T)GGTGTGAAAG	58	[24]

BIF-R	CCACATCCAGC(A/G)TCCAC

Clostridium leptum group	sg-Clept-F	GCACAAGCAGTGGAGT	53	[25]

sg-Clept-R3	CTTCCTCCGTTTTGTCAA

Bacteroides-Prevotella-Porphyromonas	BPP-F	GGTGTCGGCTTAAGTGCCAT	56	[24]

BPP-R	CGGA(C/T)GTAAGGGCCGTGC

Clostridium coccoides group	g-ccoc-F	AAATGACGGTACCTGACTAA	58	[26]

g-ccoc-R	CTTTGAGTTTCATTCTTGCGAA

Lactobacillus	Lac1F	AGCAGTAGGGAATCTTCCA	58	[27]

Lab667	CACCGCTACACATGGAG


	Mean 24-week change from baseline

	9.5 mg/24 h patch	Capsule (3–12 mg/day)	Placebo

Primary outcomes

ADAS-cog	−0.6**	−0.6**	1.0

ADCS-CGIC	3.9**	3.9**	4.2

Secondary outcomes

MMSE	1.1**	0.8**	0.0

ADCS-ADL	−0.1**	−0.5*	−2.3

Trail making test part A	−12.3***	−9.8***	7.7

Adverse events, %

Nausea	7.2	23.1***	5.0

Vomiting	6.2	17.0***	3.3


	n	%	Mean	LCI	UCI

Maternal outcomes from most recent pregnancy

 Unplanned pregnancy (n = 2039)	657	32.2

 Early booking (n = 2038)	886	43.5

 Late booking (n = 2038)	1037	50.9

 Unbooked (n = 2042)	114	5.6

 Low birth weight (n = 2007)	173	8.6

 Mean birth weight in grammes (n = 2007)			3036	3016.66	3055.85

 Premature (n = 2009)	31	1.54

 Caesarian Section (n = 2002)	65	3.25

 Extended hospital Stay (4+ days during delivery)	149	7.6

Maternal outcomes from previous pregnancies

 Age at first pregnancy (mean) n = 2042			20.22	20.09	20.35

 Gravidity (mean no. of lifetime pregnancies) (n = 2042)			2.22	2.17	2.27

 History of miscarriage (n = 2039)	234	11.5

 History of a stilbirth (n = 2038)	30	1.37

 History of a premature baby (n = 2037)	35	1.72

 History of a neonatal death (n = 2007)	188	9.37


Item	Wanted to know the sex of the baby	Did not want to know the sex of the baby	p value

Mean age, years	29.4	29.4	0.80

	n (%)	n (%)

Age groups			0.99

 17–24 years	214 (16.1)	160 (15.9)

 25–34 years	923 (69.4)	697 (69.4)

 35–47 years	193 (14.5)	148 (14.6)

Origin			0.45

 Nordic	1245 (92.1)	950 (92.3)

 Non-Nordic	107 (7.9)	79 (7.7)

Education			0.32

 Low	584 (43.3)	465 (45.5)

 High	764 (56.7)	558 (54.5)

Previous children			0.43

 No previous childen	624 (46.0)	456 (44.3)

 Has previous children	732 (54.0)	573 (55.7)

Income			0.53

 Low	620 (46.9)	485 (48.2)

 High	703 (53.1)	521 (51.8)

Pregnancy planning			0.34

 Very/fairly planned	1004 (74.7)	781 (76.4)

 Neither planned nor unplanned	180 (13.4)	139 (13.6)

 Very/fairly unplanned	160 (11.9)	102 (10.0)

Gone through another method of fetal diagnostics	594 (43.8)	388 (37.7)	<0.001

Importance of religion			0.44

 Great importance	146 (10.9)	127 (12.4)

 Neither important nor unimportant	296 (22.0)	231 (22.5)

 Little importance	903 (67.1)	667 (65.1)


Cluster	Cluster	Voxel	Voxel

P	Size	P	T	x	y	z	Side	Location

0.008	22	0.004	5.15	−56	−18	40	L	IPL

0.011	16	0.008	5.16	−38	−42	60	L	aIPS


Demographic group	% of survey respondents who travelled to the mainland in previous 8 weeks in 2013 (N)	% of survey respondents who travelled to the mainland in previous 8 weeks in 2014 (N)

Overall	8.1% (20,536)	8.7% (20,880)

Children aged 2-14	6.2% (7,555)	6.1% (8,039)

Aged 15 or over	9.6% (11,498)	10.9% (11,436)

Living in urban sites	10.9% (12,080)	11.9% (12,309)

Living in rural sites	4.0% (8,456)	4.1% (8,571)

Highest SES quintile	9.8% (4,686)	14.3% (5,496)

Lowest SES quintile	3.9% (2,499)	4.6% (2,974)


S.N.	Name of genotype	Pedigree/source

 I. Elite coffee genotypes used for genetic diversity in the cultivated genepool

1	Taferikela	C. arabica; Pureline from Ethiopian collections

2	HdeT	C. arabica; Amphidiploid coffee, a natural hybrid from C. arabica and C. canephora

3	S2790	C. arabica; HdeT × Tafarikela, selection

4	S2792	C. arabica; Tafarikela × HdeT, selection

5	S10	C. arabica; Double Cross Hybrid; Caturra with Cioccie and S.795 (both arabica)

6	S11	C. arabica; Amphidiploid, C. liberica × C. eugenioides

7	BM	C. arabica; Blue Mountain Pure line

8	Agaro-Sln4	C. arabica; Pureline from Ethiopian collections

9	Kagganahalla	C. canephora; Selection

10	BR9	C. canephora; Selection

11	BR11	C. canephora; Selection

12	CXR	C. canephora; Hybrid of C. congenis × C. canephora

13	L1Valley	C. canephora; Selection

14	S3329	C. canephora; Selection

15	S3334	C. canephora; Selection

16	Sln27	C. canephora; Pure line

 II. Parents and mapping population used for testing utility in mapping analysis

 Parents: CXR (12) and Kagganahalla (9); Mapping population: 175 segregating progenies

 III. Species of Coffea and Psilanthus (related taxa of cultivated coffee) used for transferability studies

a	C. congensis	Erythrocoffea (W. & C. Africa)

b	C. excelsa	Pachycoffea (Srilanka)

c	C. liberica	Pachycoffea (W. & C. Africa)

d	C. abeokuteae	Pachycoffea (Srilanka)

e	C. dewevrei	Pachycoffea (USDA)

f	C. arnoldiana	Pachycoffea (SanMarino)

g	C. aruwemiensis	Pachycoffea (SanMarino)

h	C. eugenioides	Mozambicoffea (C. Africa)

i	C. racemosa	Mozambicoffea (E. Africa)

j	C. salvatrix	Mozambicoffea (E. Africa)

k	C. kapakata	Mozambicoffea (C. Africa)

l	C. stenophylla	Melanocoffea (W. Africa)

m	P. wightiana	Paracoffea (India)

n	P. bengalenis	Paracoffea (India)


Description	Answers	p-value model	ORb	95 % CIc

Work sequence depending on healthy before sick pigs (Ref.a Yes)	No	<0.01	16.68	3.4-81.8

Working on other farms (Ref. No)	Yes	<0.01	0.05	0.006-0.4

Distance to the next pig farm (Ref. ≥ 500 metres)	<500 metres	0.01	9.88	1.7-57.1

Visitor boots available (Ref. No boots available)	Yes, clean	0.97	1.03	0.2-4.7

	Yes, dirty	0.01	0.06	0.006-0.5

Analysis of production parameters (Ref. by others (external))	By farmer (program, computer, written, none)	0.01	0.12	0.02-0.6

Application of homoeopathic agents (Ref. Yes)	No	0.02	10.49	1.4-78.8

Mixing pigs of different suppliers within the same pen (Ref. No mixing)	Yes	0.05	4.16	1.0-17.4


Zebrafishglucose-related immune protein	p-value	GO annotation

gpia	0.004833	humoral immune response

hif1ab	0.0065	inflammatory response

ins	0.006833	glucose transport/T cell activation


Genus	Species	Name	Feeding Strategy	Genome Size (Mb)	Proteome size	CWDE’s Identified

Bursaphelenchus	B. xylophilus	Pine wood nematode	Stem/Bulb Nematodes	73.09	18,074	119

Globodera	G. pallida	Potato cyst nematode	Sedentary Endo-parasites	123.63	16,417	100

Meloidogyne	M. floridensis	Peach root-knot nematode	Sedentary Endo-parasites	96.67	21,038	102

M. hapla	Northern root-knot nematode	Sedentary Endo-parasites	53.01	14,420	78

M. incognita	Southern root-knot nematode	Sedentary Endo-parasites	82.1	20,365	131


	Overall (%)

Returned home with the presence of adults	42.3

Returned home without the presence of adults	12.5

Returned home with the presence of siblings	10.9

Participated in extracurricular activity	23.5

Socializing with friends without the presence of adults	9.9

Wandering the streets alone	0.9


Type of Tool	Respondents	Number of Interviews (Key Informat Interviews)	Number of participants per interview	Total number of participants

Key Informat Interviews	Medical Officers, Clinical Care Experts and Maternal and Child Health Cordinator	12 (3 in each of the 4 districts)	1	12

Health Facility in-charge	4 (1 in each of the 4 districts)	1	4

Focus Group Discussions	Mothers of children below one year	4 (1 in each of the health facilities from each district)	8–10	38

Community Health Volunteers (CHWs, NHC, TBAs)a	4 (1 in each of the health facilities from each district)	6–8	30

Total	24	84


Type of organization	Organization/department	Position	No. of interviewees

National Ministry of Health	Monitoring and Evaluation	Head, M&E	1

	Health information system	Head, HIS	1

	Health Financing	Head, Health financing division	2

National Treasury	IFMIS		2

	e-PROMIS	Director	1

Social Insurance Agency	National Hospital Insurance Fund		1

University of Nairobi	School of Economics	Senior Lecturer	1

	School of Public Health	Head, Health system and policy department	1

Tertiary Hospital	Kenyatta hospital		1

Multilateral organizations	WHO	Health System Advisor	1

	World Bank	Regional Health Specialist	1

	DFID	Secretary, Health & Education departments	1

USAID or PEPFAR funded	Abt Associates		1

 implementers	i-TECH		1

	Futures group		3

Nairobi County	Mbagathi District Hospital		4

Kajiado County	County administration		2

	Hospital	Health administration officer	1

Muranga County	County administration		2

	Muranga County Hospital	Medical Superintendent	1

Nakuru County	County administration		1

	Nakuru Regional Hospital		2

TOTAL			32


CT score	CT status	Morphology features on CT	EMVI status

0	Definite No	Absence of tumor extension beyond the colon wall/ Tumor extension through the colon wall but no adjacent vessels (Mesenteric contralateral side)	Negative

1	Suspicious No	Stranding in proximity of vessels but no tumor density in vessels (Mesenteric side)	Negative

2	Suspicious Yes	Similar tumor density in adjacent vessels; vessel expansion by tumor (Mesenteric side)	Positive

3	Definite Yes	Similar tumor density in adjacent vessels; Irregular vessel contour by tumor (Mesenteric side)	Positive


	United States	United Kingdom	Canada	International

Source	U.S. government	The Medical Letter	U.K. government	Canadian government	World Health Organization

Primaquine as Primary Prophylaxis	As an alternative to suppressive options or:With travel where malaria is primarily P. vivaxShort-term travelShort-notice travel	Only as an alternative to suppressive options	Not recommended	Only as an alternative to suppressive options	None specified except for special risk groups (infants, pregnant women, vulnerable children in seasonal high transmission)

Primaquine following a diagnosis of P. vivax	Recommended	Recommended	Recommended	Recommended	Strongly recommended

Primaquine following suppressive prophylaxis	Recommended	No recommendation	Not recommended	Recommended for high risk groups	No recommendation

References	[21]	[22, 23]	[24, 25]	[26]	[27]


	Number (%) of facilities assessed in evaluation

	2010	2012

Total	52	50

Region:

Tanga	6 (12)	6 (12)

Arusha	5 (10)	5 (10)

Lindi	3 (6)	3 (6)

Morogoro	5 (10)	5 (10)

Manyara	5 (10)	4 (8)

Iringa	4 (8)	4 (8)

Tabora	6 (12)	6 (12)

Kilimanjaro	5 (10)	5 (10)

Kigoma	3 (6)	3 (6)

Pwani	3 (6)	3 (6)

Mtwara	3 (6)	3 (6)

Ruvuma	4 (8)	4 (8)

Facility type:

Regional hospital	12 (23)	12 (24)

Health centre/Dispensary	40 (77)	38 (76)


Characteristics	Number	Percentage (95% confidence interval [CI])

Total n	138

Median age (y)	30 (16–41)

Median gravidity	2 (1–9)

Median parity	1 (0–5)

Race/ethnicity

 Non-Hispanic White	114	82.6 (75.4–88.1)

 Non-Hispanic African-American	23	16.7 (11.3–13.8)

 Other	1	0.7 (0–4.4)

Type of insurance

 Private	97	70.3 (62.2–77.3)

 Medical assistance	41	29.7 (22.7–37.8)

Obstetrical provider Type

 Private physician	100	72.5 (64.5–79.3)

 Maternal fetal medicine	3	2.2 (0.5–6.5)

 OB/GYN residents	25	18.1 (12.5–25.4)

 Midwife 	8	5.8 (2.8–11.2)

 Family practitioner	2	1.4 (0.07–5.5)

Type of delivery

 Vaginal	116	84.1 (77.0–89.3)

 Cesarean after labor	22	15.9 (10.7–23.0)

Patient documentation of nature of the penicillin allergy	78	56.5 (48.2–64.5)

Patients with documentation that they received antibiotic prophylaxis	135	97.8 (93.5–99.5)

Type of antibiotics received

 Cephalosporin	41	30.4 (23.2–38.6)

 Clindamycin	54	40 (32.1–48.4)

 Erythromycin	2	1.5 (0.07–5.6)

 Vancomycin	36	26.7 (19.9–34.7)

 Penicillin	2	1.5 (0.07–5.6)


Characteristic	N	%

VTE event type

 Lower extremity DVT	37	37.4

 Pulmonary embolism	26	26.3

 Portal vein thrombosis	2	2

 Upper extremity DVT	26	26.3

 Other venous thrombotic episode	8	8.1

Median time to thrombocytopenia (days)	89.5	NA


Variable	Frequency	Percentage

Recording condition of the baby after birth

 Yes	203	84.9

 No	36	15.1

Mode of delivery

 SVD	181	75.7

 C/S	23	9.6

 Note recorded	35	14.6

Fetal outcome

 Alive	192	80.3

 Dead	3	1.3

 Not recorded	44	18.4

Active management of third stage of labour

 Yes	133	55.6

 No	106	44.4

Sex of the new born

 Recorded	189	79.1

 Not recorded	50	20.9

Weight of the new born

 Recorded	192	80.3

 Not recorded	47	19.7

Time of delivery

 Recorded	202	84.5

 Not recorded	37	15.5

APGAR score

Good (7–10)	195	81.6

Not good (1–6)	3	1.3

Not recorded	41	17.2


Variables	n with information	%

Place of residence

Plak-Ô	33	66.0

Terra Nova	64	34.0

Gender

Male	44	45.4

Female	53	54.6

Age

<2 years	32	33.0

≥2 years	65	67.0

Garbage collection

Adequate	-	-

Inadequate	97	100.0

Birthplacea

Maternity/hospital	94	97.9

Home	2	2.1

Vitamin A supplementationa

Yes	67	77.0

No	20	23.0

Iron deficiency anemia

No	41	42.3

Yes	56	57.7

Presence of parasitic infestationa

No	24	32.9

Yes	49	67.1


Gene	Forward Primer	Reverse Primer

Slc22a1	TCTGGCTACAGGAGAACGACGGCCA	TGCTCCATTATCCTGACAGCTCGCGT

Slc22a2	TCGAAACAGAGGAGGATTGTGGGAATA	GAGAGGTGTTTCCCATTGCACTTAGCCAC

Slc22a6	TATGTGGGCACCTTGATTGGC	AGGGTGAGGTCCAGCCTTCCT

Slc22a8	ATCTCATCAACATCTATTGGG	AGGGCCTTTGAGTATTTTCCA

Slco1a1	TATGGAGGACAAGCCAGAGAG	AGAGGTGGTTAATCCAGCAAC

Slco1a2	CACAGAAAAAAGGCCAAGGAA	TAAGGAAAGACAGAAGGTACT

Slco1a5	CACAGAGAAAAAGCCAAAGAG	AGAGGCAGTTAAGCCGGCAAC


Mycotoxigenic Fungi	Corn Silage	Barley Silage	Hay

Fusarium culmorum	100	0	0

F. poae	0	100	100

F. verticillioides	0	100	0

F. sporotrichioides	0	100	0

Aspergillusflavus	100	20	0

Penicillium roqueforti	100	100	100

P. crustosum	20	0	20

P. paneum	20	0	20

P. citrinum	50	25	0


ICD-9 procedure code	N = 50,225^ n (%)	Description

41.31	5,185 (10.3%)	Biopsy of bone marrow

38.93	4,066 (8.1%)	Venous catheterization, not elsewhere classified

01.59	3,160 (6.3%)	Other excision or destruction of lesion or tissue of brain

03.31	2,705 (5.4%)	Spinal tap

86.07	2,264 (4.5%)	Insertion of totally implantable vascular access device [VAD]

85.05	1,147 (2.3%)	Incision with removal of foreign body or device from skin and subcutaneous tissue

02.2	1,076 (2.1%)	Ventriculostomy

40.11	1,038 (2.1%)	Biopsy of lymphatic structure

40.3	827 (1.7%)	Regional lymph node excision

54.4	819 (1.6%)	Excision or destruction of peritoneal tissue


Recommended timeline	Building the infrastructure	Educational development	Program accreditation	Marketing and recruitment

6–12 months	Institutional affiliation and training site

	Budget/funding Timeline

3–4 months		Review and apply ACGME requirements

		Develop your educational vision

4–6 months		Curriculum and program design	Complete the application

2–3 months		Faculty development	Prepare for site visit

3–6 months			Await accreditation decision	Strategic marketing

8 months (July–February)				Active recruitment

4 Months (March–June)				The beginning: match and orientation


Harvestable amount	pH	OM	TN 	P2O5

Root length	0.452	0.888∗∗	0.921∗∗	0.630


Case	Fracture type	Time to fracture (mo)	Treatment	Plates	Bone graft	Time to union (mo)	Duration of follow-up (mo)	Outcome	JOA score

1	Oblique	104	ORIF	DFLCP	-	4	22	Union	63

2	Transverse	100	ORIF	Reverse DFLCP	Auto, fibula	6	28	Union	77

3	Transverse	75	Revision (IBG) +ORIF	LCP	Allo, auto, iliac	3	119	Union	68

4	Transverse (with stem fracture)	88	Revision (IBG)	-	Allo	4	45	Union	77

5	Transverse	78	ORIF	Dall-Miles plate	Auto, fibula	7	115	Nonunion*	53

6	Oblique	99	ORIF	LCF	Auto, iliac	4	74	Union	60

7	Transverse	12	ORIF	Dall-Miles plate	Auto, fibula	8	180	Union	67

8	Oblique	120	ORIF	DFLCP	Allo	4	35	Union	60

9	Oblique	142	ORIF	DFLCP	-	4	10	Union	62

10	Transverse	114	ORIF	Reverse DFLCP	Auto, iliac	6	12	Union	72

11	Oblique	240	ORIF	DFLCP	-	2	8	Union	81


	Total

Characteristic	n	IR	IRR	95% CI

Total	338	0.92	NA

Race

 Whites	295	0.97	1.00	Reference

 Blacks	20	0.59	0.61	0.37 to 0.96

 Other/unspecified	23	~	~	~

Calendar period

 1977 to 1986	79	0.78	1.00	Reference

 1987 to 1996	121	1.02	1.30	0.97 to 1.76

 1997 to 2006	138	0.96	1.23	0.93 to 1.65

Age

 <50 years	59	0.25	1.00	Reference

 ≥50 years	279	2.70	11.02	8.31 to 14.87

Laterality

 Right	164	0.45	1.00	Reference

 Left	173	0.47	1.06	0.85 to 1.32

 Not specified	1	~	~	~

Site

 Upper outer quadrant	105	0.29	1.00	Reference

 Upper inner quadrant	29	0.08	0.28	0.18 to 0.43

 Lower outer quadrant	23	0.06	0.22	0.13 to 0.35

 Lower inner quadrant	14	~	~	~

 Nipple/central	28	0.08	0.27	0.17 to 0.41

 Overlapping	89	0.24	0.83	0.62 to 1.11

 Not specified	50	0.14	0.47	0.33 to 0.67

Stage

 Localized	320	0.87	1.00	Reference

 Regional	14	~	~	~

 Distant	1	~	~	~

 Unstaged	3	~	~	~

LN and sizea

 LN negative, ≤2 cm	126	0.50	1.00	Reference

 LN negative, >2 cm	67	0.26	0.52	0.38 to 0.71

 LN positive, ≤2 cm	2	~	~	~

 LN positive, >2 cm	3	~	~	~

 Other/not specified	46	0.18	0.36	0.25 to 0.51

Hormone receptorsb

 ER-negative/PR-negative	128	0.56	1.00	Reference

 ER-negative/PR-positive	6	~	~	~

 ER-positive/PR-positive	21	0.09	0.16	0.10 to 0.25

 ER-positive/PR-negative	12	~	~	~

 Other/not specified	55	0.24	0.42	0.30 to 0.59


	Journal Name

	BMJ	Lancet	NEJM	JAMA	BJS	BJC	BJOG	Total

2007-8

Original articles	6	5	5	1	10	16	10	541 (1.6%)

Pilot or feasibility study in preparation for a trial	0	3	3	0	2	1	3	12

Piloting new technique, combination of treatments	1	0	0	0	4	2	6	13

Phase I, II trials	0	1	1	0	0	7	0	9

Piloting screening program	2	0	0	1	1	1	0	5

Piloting guidelines, educational package, patient care strategy	3	1	0	0	2	3	1	10

Laboratory testing of activity of compounds	0	0	1	0	1	2	0	4

Total research papers	292	379	444	383	338	1084	398	3318

2000-12

Original articles	11	17	3	7	9	33	10	90 (2.0%)

Total research papers	372	1115	434	619	396	1132	381	4449


Variable	Number (percent)

Gender	Male: 7 (28%)

Female: 18 (72%)

Racial/ethnic background	White: 19 (76%)

African-American: 2 (8%)

Hispanic: 1 (4%)

Asian: 3 (12%)

Highest Education level	High School or less: 3 (12%)

Some college, no degree: 3 (12%)

Associate’s degree: 11 (44%)

Bachelor’s degree: 4 (16%)

Post-graduate training: 4 (16%)

Recruitment source	Office staff: 7 (28%)

Website volunteer: 8 (32%)

Practice volunteer: 6 (24%)

Department staff volunteer: 4 (16%)

Newest Vital Sign Health Literacy category	Adequate literacy: 18 (72%)

Possible limited literacy: 5 (20%)

High likelihood limited literacy: 2 (8%)

REALM grade level	High School: 21 (84%)

7th – 8th grade: 3 (12%)

4th to 6th grade: 1 (4%)

 	Mean (sd, range)

Age, years	51.4, (13.8, 22 to 71)

Subjective numeracy scale	4 (0.75, 2.25 to 5.38)


	Number of	Lower 95% of risk

Outcome	Events	Patients	rule of 3	Exact CI

Epidural haematoma

Cardiac	0	4971	1 in 1,700	1 in 1,350

Thoracic	0	4108	1 in 1,400	1 in 1,100

Vacular	0	5026	1 in 1,700	1 in 1,350

Combined	0	14105	1 in 4,700	1 in 3,800

Permanent neurological injury

Combined	0	13827	1 in 4,600	1 in 3,750


Species	Group	NSkull	NMandible

C. australis (aus)	mendocinus	31	27

C. azarae (aza)	mendocinus	29	26

C. flamarioni (fla)	mendocinus	32	22

C. porteousi (por)	mendocinus	30	28

C. mendocinus (men)	mendocinus	24	14

C. ibicuiensis (ibi)	torquatus	16	10

C. lami (lam)	torquatus	89	66

C. minutus (min)	torquatus	197	122

C. pearsoni (pea)	torquatus	77	60

C. perrensi (per)	torquatus	9	9

C. roigi (roi)	torquatus	7	7

C. torquatus (tor)	torquatus	222	124

Total		763	515


		Percentile

Sample	No. > LOD/total (%)a	10th	25th	50th	75th	90th	95th

Maternal blood (pg/g)a	13/92 (14)	< LOD	< LOD	< LOD	< LOD	1.5	2.5

Umbilical cord blood (pg/g)a	8/65 (12)	< LOD	< LOD	< LOD	< LOD	2.3	2.5

Postpartum meconium (ng/g)b	23/83 (28)	< LOD	< LOD	< LOD	0.44	0.62	0.77


Case	MP Pulse Therapy	Prednisone	Others	Proteinuria (month)	Outcome

1		+	MMF	7	RBC, 14/HP after 15 months

2			Tripterygium	2	Normal urine test after 13 months

3		+	MMF	4	RBC, 14/HP after 20 months

4	+	+	CTX	5	Normal urine test after 17 months

5		+	Tripterygium	1	Normal urine test after 7 months

6	+	+	CTX	5	RBC, 10/HP after 15 months

7		+		4	RBC, 8/HP after 19 months

8		+	Tripterygium	2	RBC, 6/HP after 17 months

9			Tripterygium	4	Normal urine test after 13 months

10	+	+	CTX	4	Normal urine test after 15 months

11		+	MMF	4	RBC, 15/HP after 13 months


Approaches	# of selected nodes	# of Sampled records	Recall (%)	Precision (%)

hLDA	20	200	48.2	76.5

Ours without domain knowledge	20	200	61.7	82.56

Ours with domain knowledge	20	200	65.86	82.33


Male/female	21/4

Injured side

Right/left	18/7

Dominance

Right/left	21/4

Mechanism of primary injury

Bicycling	9

Simple fall	7

Sport	7

Traffic accident	2

Rockwood type in primary radiographs

II	3

III	6

IV	1

V	15

Mean age at time of injury, y (range)	44 (22–59)

Mean age at time of examination, y (range)	48 (24–63)


Level of consciousness	Example of positive collective values

7. Service: Self-less service to the world	Social responsibility, future generations, long-term perspective, ethics, compassion, humility

6. Making a difference: to the local community or health district	Collaboration, community involvement, strategic partnerships.Staff fulfilment, coaching/mentoring, leadership development

5. Internal cohesion: Building internal organisational community	Shared values, vision, commitment, integrity, trust, passion, creativity, openness, transparency

4. Transformation: Continuous renewal and learning	Accountability, adaptability, empowerment, teamwork, goals orientation, personal growth

3. Self-esteem: High performance and quality of care	Systems, processes, quality, best practices, pride in performance.Bureaucracy, arrogance, image, hoarding information

2. Relationships: With colleagues and patients	Loyalty, open communication, patient experience, friendship.Blame, internal competition, rivalry, manipulation

1. Survival: Resources and safety	Sufficient budget, equipment, employee health, safety.Control, chaos, caution, job security


	Number	Response rate

Invitational e-mails sent	1345	17% (227/1345)

Valid emails addresses	1131	20% (227/1131)

Emails opened	693	33% (227/693)

Links to survey opened	293	77% (227/293)

Participants that completed survey	227


	III.2	III.3	III.6	III.7	III.8 (Proband)	III.9

Lab ID	PI-2568	PI-2569	PI-2570	PI-1202	PI-1124	PI-2571

Gender	F	F	F	M	M	F

ATXN10 repeat (SMRT/Cas9 capture)*	1315	1363	1076	1363	1304	1080

Age at onset (years)	35	48	unaffected	48	38	37

Onset of seizures (years)	60	57	–	53	–	–

Current age (years)	71	68	61	65	57	53

Duration of disease (years)	36	20	–	17	19	16

Seizures	+	+	–	+	–	–

Gait ataxia	+	+	–	+	–	+

Intention tremor	+	+	–	–	+	–

Dysarthria	+	+	–	+	–	+

Dysmetria	+	+	–	+	–	+

Dysdiadochokinesia	+	+	–	–	+	+

Nystagmus	+	+	–	+	–	+

Ocular dyskinesia	+	+	–	+	–	–

Hypotonia	–	–	–	–	–	–

Hyperreflexia	–	–	–	+	–	–

Babinski’s sign	–	–	–	–	–	–

Leg spasticity	–	–	–	–	–	–

Aggressiveness	+	+	–	–	–	+

Depression	+	+	–	+	+	+

MoCA	9/30	2/30	29/30	U	U	25/30

SARA	23.5/40	24.5/40	0/40	U	6/40	16/40

B-SIT (% tile)	NP	NP	27%	U	29%	20%

B-SIT (category)	NP	NP	Normal	U	Normal	Normal


Species and tissue or cell type	Relevant properties of tissue or cells	Name of library in NCBI and contributor(s)	Total number of ESTs per library (March 2006)	Number of ESTs matching genes in Arabidopsis (e < 10-7)	Number of contigs identified using CAP3	Number of singletons identified using CAP3	Unigenes (contigs plus singletons)

Zea mays

Sperm	Male	Zea mays sperm cell cDNA library (S. McCormick) Engel et al.[64]	5174	2457	384	781	1165

Egg	Female	Zea mays egg cell cDNA library (H. Yang and S. McCormick) Yang et al. [65]	4085	1957	264	863	1127

Triticum aestivum

Anther-meiotic	Male	Wheat meiotic anther cDNA library (O. Anderson)	9139	6118	860	3058	3918

Ovary	Female	Ov (Genoplante)	5311	3699	813	1295	2108

Brassica napus

Microspores (from 3 to 4 mm buds)	Male	65JKBNM0 (M. Malik and J. Krochko)	6539	5325	781	1620	2401

Buds and young flowers	Heterogeneous (male, female and somatic)	ADIS-MPIZ 021 (B. Weisshaar)	8747	6164	995	2665	3660


 	Body weight (g)	GHb (%)	Urine volume (ml/24 hours)

Normal	618 ± 71	5.7 ± 0.6	9 ± 8

Diabetes	369 ± 65	11.1 ± 2.1*	106 ± 20*

Diab + Nutr	354 ± 63	9.8 ± 2.4*	92 ± 42*


	Average gold-standard	Average real-time	Wilcoxon p-value

For all subjects (63/63)

Endocardial border	3.9	3.9	0.23

Papillary muscle	4.0	3.9	0.03*

Blood pool	4.0	3.6	<0.001*

Mitral valve	3.9	3.4	<0.001*

Myocardium	3.9	3.9	0.45

Cardiac motion	3.9	3.9	1.00

Radial GRAPPA with 26 calibration frames (23/63)

Endocardial border	3.9	3.9	0.73

Papillary muscle	4.0	4.0	0.71

Blood pool	4.0	3.7	<0.01*

Mitral valve	3.8	3.2	<0.001*

Myocardium	3.9	4.0	0.17

Cardiac motion	3.9	4.0	0.14

Radial GRAPPA with 6 calibration frames (40/63)

Endocardial border	4.0	3.9	0.05

Papillary muscle	4.0	3.9	0.02*

Blood pool	4.0	3.6	<0.001*

Mitral valve	3.9	3.5	<0.001*

Myocardium	4.0	3.9	0.07

Cardiac motion	4.0	3.9	0.23


 	Stepwise multiple regression	Predictor variables

 	Model	 	 	 	Variable	Beta	P

F	df	P	R2

B cells all	21.650	3	0.000	0.391	CXCL13	0.745	0.000

CXCL12	−0.490	0.001

BAFF	0.320	0.012

B cells	18.098	2	0.000	0.262	CXCL13	0.616	0.000

 	 	 	 	 	CXCL12	−0.271	0.010

Plasmablasts	20.265	2	0.000	0.287	CXCL13	0.413	0.000

 	 	 	 	 	BAFF	0.234	0.009

T cells	6.001	2	0.003	0.110	BAFF	−0.498	0.001

 	 	 	 	 	APRIL	0.296	0.05

Monocytes	 	 	 	 	No variables included


Endpoint	Exposure conditions	Results of exposure	Comments	Reference

Weight gain, survival, in SD rats, urinalysis, hematology, blood biochemistry after exposure	849 MHz CDMA and 1.95 GHz WCDMA, 45 min/day, 5 days/week for 1 year, at 2 W/kg per signal, animals freely moving, am or pm alternately	No significant effects except significant increase in mean corpuscular hemoglobin level and alkaline phosphatase in males, and significant decrease in total bilirubin and lactate dehydrogenase in females		(48)

Weight gain, survival, lymphoma incidence in AKR/J mice, blood biochemistry after 26 weeks of exposure, metastatic infiltration by IHC	849 MHz CDMA and 1.95 GHz WCDMA, 45 min/day, 5 days/week for 42 weeks, at 2 W/kg per signal, animals freely moving, am or pm alternately	No significant effects. Significant decrease in metastatic infiltration in brain of males, increase in females, not due to exposure		(49)


 	TJ-54 (n = 48)	Placebo (n = 50)	Test statics

Age (years)	46.4 ± 9.7	5.4 ± 9.6	ns

Gender (males/females)	28/20	32/18	ns

Duration of disease (years)	23.7 ± 10.4	22.5 ± 9.6	ns

Duration of treatment (years)	3.2 ± 10.5	21.0 ± 10.3	ns

CPZ equivalents (mg)	1905.8 ± 1541.5	1941.8 ± 1948.1	ns

Type

Paranoid	39	35

 Catatonic	6	5

 Undifferentiated	3	10	ns

PANSS (total)	113.0 ± 23.0	111.1 ± 21.1	ns

PANSS (positive)	28.6 ± 5.4	28.7 ± 6.0	ns

PANSS (negative)	27.9 ± 7.1	27.8 ± 7.3	ns

PANSS (general)	56.6 ± 13.3	54.6 ± 11.9	ns

CGI-S	5.4 ± 0.8	5.5 ± 0.8	ns

GAF	27.4 ± 7.5	27.2 ± 6.4	ns

DIEPSS	4.3 ± 4.0	4.8 ± 4.5	ns


No.	Strain	Species	Culture conditions	Active acidity	Bacteriocin production

S1	CCDM 731	Lactococcus lactis subsp. Lactis	37°C 18 h	M17 broth	4.65	Nisin

S2	CCDM 857	Enterococcus faecalis		M17 broth	4.51	Enterocin

S3	CCDM 108	Lactobacillus helveticus		MRS broth	4.14	Enterocin

S4	RL 26-P	Lactobacillus plantarum		MRS broth	3.67	Plantaricin

S5	CCM 7165	Enterococcus faecium		M17 broth	4.68	Enterocin

S6	RL 23-P	Lactobacillus sp.		MRS broth	4.11	Plantaricin

S7	CCDM 768	Lactobacillus helveticus		MRS broth	4.07	Enterocin

S8	CCDM 182	Lactobacillus plantarum		MRS broth	3.81	Plantaricin

S9	RL 22-P	Lactobacillus gasseri		MRS broth	4.51	Plantaricin


Cross	Generation	No. of total plants	No. of dwarf plants (< 60 cm)	No. of high plants (≥60 cm)	χ2 (1:1)

(Huaai11/Monker)/Huaai 11	BC1	135	62	73	0.90

(Huaai11/Monker)/Aiganqi	TC1	119	0	119	0

(Huaai 11/Monker)/Himalaya	TC1	157	0	157	0

(Huaai 11/Monker)/Indian dwarf	TC1	117	0	117	0

(Huaai 11/Monker)/Maris Mink	TC1	143	0	143	0


Rat Number	Treatment	Hemisphere	Frequency (kHz)	Voltage (V)

1	IRE	Left	-	100

	H-FIRE	Right	250	100

2	IRE	Left	-	200

	H-FIRE	Right	250	200

3	H-FIRE	Left	250	300

	H-FIRE	Right	250	400

4	IRE	Left	-	50

	H-FIRE	Right	500	400


	Standard of care (SOC)	Community-based intervention (CBI)

Adult patients asked to bring child contacts to TB clinic for screening	X	X

Child contacts screened with symptom questionnaire	X	X

IPT offered to eligible child contacts	X	X

Monthly IPT visits	X	X

HIV testing encouraged for eligible child contacts	X	X

Active community contact tracing		X

Community-based health education using study brochure		X

Child screening and IPT provision according to clinical algorithm		X

Nurse training and ongoing mentorship		X

Health education for caregivers using treatment literacy curriculum		X

Active tracking of IPT provision		X

Consistent community support via VHW		X

Social support and navigation by VHW		X

SMS medication and appointment reminder messages		X

Review of IPT monitoring data at quarterly multidisciplinary team meetings		X


Socio-Demographic Characteristics	Total n = 60

Age Range (Min, max)	70–97

Mean (SD)	77 (6.27)

Sex, n (%)

Female	40 (66.7)

Male	20 (33.3)

Educational Level, n (%)

High school or less	48 (80)

Some college education	12 (20)

Monthly Income, n (%)

Low(<$1000)	50 (83)

Medium ($1000–$2000)	8 (13)

High (>$2000)	2 (3)

Health Conditions, n (%)

Hypertension	35 (58)

Musculoskeletal	33 (55)

Diabetes	32 (53)

Visual	15 (25)

Respiratory	13 (23)

Cardiac	12 (20)

Overweight	12 (20)


Gene Contributes to Core Enrichment	Gene Does Not Contribute to Core Enrichment

BMP4	SP1	ACTB	GJA1	PDPK1

BMP6	TBXAS1	AKAP1	GNAS	PECAM1

CCL2	TGFB1	ANXA2	GNB2	PFDN5

CD34	THBD	ANXA5	GNG5	PTGS2

CENPF	THBS1	APOE	GRN	RGS5

CTGF	TRA1	APS	HADHSC	RPL30

CXCL12	TUBG1	ARF4L	HMOX1	RPL34

CYP1B1	VCAM1	ASS	ICAM1	RPS11

CYR61	VIPR1	CAV1	IFITM3	RPS7

DPYSL3	XPO1	CCL15	IL13RA1	SAT

EDN1		CCL25	IL15	SCGF

EEF1A2		CD164	IL16	SELE

ELN		CD1D	IL1R1	SERPINE1

F3		CD58	IL1RL1	SERPINE2

FGF2		CD68	ITGB3	SLC35F2

FN1		CDKN1A	JARID1A	SMARCD1

GAPD		CEACAM1	JUN	SOD2

GBP1		CYP1A1	KLF2	SPARC

GJA5		DKK2	LAMB1	SPTA1

GSTP1		E2F5	LIMS1	SPTAN1

IL8		EDN3	LRP2	STAM

ILK		EFEMP1	METAP2	TEK

JAG2		EGR1	MGP	TFPI

JUNB		EIF4EBP2	MMP1	TGFB1I4

KIF20A		EIF4G3	MMP14	THBS4

KLF4		ESM1	MMRN1	TNFRSF1A

LIG3		F2	MYD88	TNFRSF5

MAPRE1		F2R	NFKB1	TNFSF8

MATN2		FGF6	NOTCH4	TUBA3

MYC		FGFR3	NQO1	TXNRD1

NOS3		FLT1	NUMA1	UNG

PFDN2		FOS	OGT	VCL

PLAT		FOSL1	OLR1	VEGFC

RGS3		FTH1	PBP	VWF

RHOA		FTL	PCQAP	WNT2B

RHOB		GARS	PDGFRA

S100A10		GAS	PDGFRB


Study	Adequate sequence generated?	Allocation concealment?	Blinding of participants and personnel?	Blinding of viral load assessment?	Incomplete outcome data addressed? (Missing at follow up = treatment failure)	Free of other bias?

Jaffar et al. [37]	Yes.	Yes.	No.	Yes.	No.	Yes.

Cards were sealed in advance and labelled with stratum numbers and placed into a box	Sealed cards were drawn from a concealed box.	The study was cluster randomized trial; researchers and participants knew which clusters were receiving the interventions.	Probably done, because Blood taken for viral load testing was for research purposes; the testing was done in batches rather than in real-time.	“Those who withdrew or were lost to follow-up before 12 months were excluded from the primary endpoint analysis...”	The two groups were well balanced according to baseline characteristics apart from CD4-cell count, which was lower in the home-based than in the facility-based group [39]. There were no losses of clusters. The analysis adjusted for the effect clustering

Nachega et al. [35]	Yes.	Yes.	No.	Unclear.	Yes.	No.

Probably done, because there was sequential allocation concealment	“[T]reatment assignments were placed in opaque envelopes, which were sequentially opened by the study coordinator at enrolment.”	The study was an open-label, randomized controlled trial; both the researchers and the participants knew which intervention was being administered.	Measurement of viral loads performed was every 6 months as part of routine monitoring	Missing viral load values were considered detectable.	Trial terminated early for futility by an independent Data and Safety Monitoring Board

Chang et al. [38]	Yes.	Yes.	No.	Unclear.	No.	No.

An allocation sequence was generated	Random allocation was by drawing of lots.	The study was cluster randomized trial; researchers and participants knew which clusters were receiving the interventions.	"Viral loads ... were performed every 24 weeks on all patients as part of routine patient monitoring procedures."	Those who died or were lost to follow-up were excluded from the analysis of shorter-term virologic outcomes	Contamination in the control arm was reported in subsequent evaluation study [40].

Taiwo et al. [36]	Yes.	Yes.	Yes.	No.	Yes.	Yes.

“Using a computer-generated allocation sequence, randomization was performed ...”	Probably done, because there was computer-generated allocation sequence.	“The study pharmacist, who was blinded to treatment arm, provided one-on-one reinforcement of the education provided by the adherence counsellor plus information specific to each participant’s regimen.”	Probably not done because patients who had detectable viral loads at week 24 underwent intensive adherence retraining with the adherence counsellor.	“[P]articipants who were missing virologic indicators and were reported to have died were counted as failures.”	There were no significant differences between treatment groups at baseline.

Matovu et al. [17]	Yes.	Unclear.	No.	Unclear.	No.	No.

Probably done, because patients were randomly allocated.	Insufficient information to permit judgement of “Yes” or “No”.	The study was an open randomized non-inferiority intervention trial.	Insufficient information to permit judgement of “Yes” or “No”.	Patients lost to follow-up were excluded from the analysis.	Baseline viral load was adjusted for. This means there were significant differences in viral loads between intervention groups at baseline.


		pI

Spot	Relative zymolytic level	Without phosphatase	After phosphatase treatment

1	18	5.005	5.129

2	13	5.048	5.175

3	52	5.110	5.228

4	13	5.169	5.276

5	5	5.226	5.330


Cases	Sex/Age	Site	Depth	Largest diameter (cm)	Immunohistochemistry	Karyotype

1	M/59	Paratesticular	Subcutaneous	5.5	CD34 Positive	45,XY,add(5)(p13~15),-7,der(13)t(1;13)(q12~21;q14~21),-14,der(16)t(7;16)(q11;q22),del(18)(q21),+mar[9]/46,XY[2]

S100 Negative

ER Negative

PGR Negative

2	M/79	Scrotum	Subcutaneous	7	CD34 Positive	46,XY,t(10;15)(p13;q22),del(13)(q12q22)[15]

S100 Negative

ER Focal positive (20%)

PGR Focal positive (10%)


HA concentration, %	HA/DVS weight ratio	ξ (nm)

5	10 : 1	223 ± 5

5	5 : 1	94 ± 6


	Small ponds	Large ponds

Taxonomic groups	Periphyton	Phytoplankton	Periphyton	Phytoplankton

Chlorophytes	p > 0.05	p = 0.045	p = 0.013	p = 0.004

Euglenophytes	p > 0.05	p > 0.05	p = 0.021	p > 0.05

Diatoms	p = 0.013	p > 0.05	p > 0.05	p > 0.05

Dinophytes	p = 0.001	p = 0.038	p > 0.05	p > 0.05

Cyanoprocaryotes	p > 0.05	p > 0.05	p = 0.023	p = 0.020


	Pairs	Trios

HGDP reference	0.0009	0.0026

Reich2012 reference	0.0013	0.0034


Measurement	Single measure ICC (2,1)	95% CI	SEM cm (mm)

Right shoulder (1st measurement)	.92	.86 to .96	0.40 (4 mm)

Left shoulder (1st measurement)	.93	.88 to .96	0.37 (4 mm)

Dominant shoulder (1st measurement)	.93	.86 to .96	0.38 (4 mm)

Non dominant shoulder (1st measurement)	.92	.87 to .96	0.39 (4 mm)

	Average measure ICC (2,3)	95% CI	SEM cm (mm)

Right shoulder (mean of 3)	.96	.93 to .98	0.29 (3 mm)

Left shoulder (mean of 3)	.92	.94 to .98	0.28 (3 mm)

Dominant shoulder (mean of 3)	.96	.94 to .98	0.29 (3 mm)

Non dominant shoulder (mean of 3)	.96	.93 to .98	0.28 (3 mm)


Clinical signs and symptoms (%)	Percentage positivity (%)

DF (n = 145)	DHF (n = 74)

Headache	89.5	95.4

Retroorbital pain	58.3	69.3

Nausea/vomiting	72.7	75.5

Rash	6.6	13.1

Abdominal pain∗	29.3	48.0

Sore throat	18.2	28.5

Lethargy	82.5	89.4

Myalgia	84.6	91.8

Arthralgia	85	88.1

Red eyes	25.8	20.9

Ecchymosis/bruising	2.3	1.6

Bleeding	8.7	15.9


			Diagnostic group	Comparison

			22q11.2DS	Controls	t test	Pearson’s chi-square	ANOVA	p value

N			95	100

Gender (male (%))			45 (47.36 %)	48 (48 %)		0.008		0.930

Age at first time point (mean (SD))			12.80 (4.23)	13.17 (4.43)	0.596			0.552

Full-scale IQ at first time point (mean (SD))			70.71 (12.27)	110.37 (13.62)			454.57	<0.001

VABS outcome measure at last time point (mean (SD))		ABC score	66.73 (12.53)

		Communication score	71.17 (17.00)

		Daily living skills score	71.06 (15.22)

		Socialization score	73.83 (14.51)

Psychiatric diagnosis (N (%))		Simple phobia	42 (44.21 %)

		Attention deficit disorder	36 (37.89 %)

		Generalized anxiety	16 (16.84 %)

		Major depressive episode	13 (13.68 %)

		Psychosis	8 (8.42 %)

		Obsessive-compulsive disorder	7 (7.37 %)

Psychotropic medication	Total		39 (41.05 %)

	Categories	Methylphenidate	26 (66.66 %)

		Antidepressants	12 (30.77 %)

		Antipsychotics	7 (17.95 %)

		Antiepileptic	7 (17.95 %)

		Anxiolytic	3 (7.69 %)


Variable	RMP	CI 95%	P

Gender

 Male	1

 Female	23.6	6.9–81.1	<0.05

Occupacion

 Other	1

 Housewife	22.8	4.9–106.1	<0.05

Contact with Stagnant Water

 No	1

 Yes	5.2	1.7–15.9	<0.05

Contact with Urine or Excrement

 No	1

 Yes	5.1	1.9–13.1	<0.05